_MEMBER_att_D_no_prior_0 - 1.8-2.2,_MEMBER_att_D_no_prior_0 - 4.5-5.5,_MEMBER_att_D_no_prior_0 - 9.0-11.0,_LogP_att_D_no_prior_0 - 1.8-2.2,_LogP_att_D_no_prior_0 - 4.5-5.5,_LogP_att_D_no_prior_0 - 9.0-11.0,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,1,-8.6,-7,-2.6,GO:0002764,immune response-regulating signaling pathway,M111,3,0
1,1,1,-4.9,-5.2,-3,M60,PID NFAT TFPATHWAY,M111,3,0
1,1,1,-6.7,-2.3,-2.1,GO:0002218,activation of innate immune response,M111,3,0
1,1,1,-8.8,-4.8,-3.7,GO:0045165,cell fate commitment,M111,3,0
1,1,1,-5,-2.3,-2,GO:0007162,negative regulation of cell adhesion,M111,3,0
1,1,1,-3.6,-4,-3.5,GO:1902106,negative regulation of leukocyte differentiation,M111,3,0
1,1,1,-5.3,-3.4,-2.3,hsa04625,C-type lectin receptor signaling pathway,M111,3,0
1,1,1,-7.7,-6.2,-2.7,hsa04662,B cell receptor signaling pathway,M111,3,0
1,1,1,-8.9,-2.1,-3.6,hsa04620,Toll-like receptor signaling pathway,M111,3,0
1,1,1,-2.3,-4.6,-2.8,GO:0070670,response to interleukin-4,M111,3,0
1,1,1,-8.6,-2.6,-2.2,GO:0031349,positive regulation of defense response,M111,3,0
1,1,1,-2.8,-6,-2.7,GO:0042113,B cell activation,M111,3,0
1,1,1,-12,-13,-3.3,GO:0042110,T cell activation,M111,3,0
1,1,1,-3.1,-3.5,-4.1,GO:2001185,"regulation of CD8-positive, alpha-beta T cell activation",M111,3,0
1,1,1,-2.1,-3.6,-2,GO:0002443,leukocyte mediated immunity,M111,3,0
1,1,1,-4.4,-3.7,-2.9,R-HSA-9674555,Signaling by CSF3 (G-CSF),M111,3,0
1,1,1,-3.7,-3.2,-4,GO:0032655,regulation of interleukin-12 production,M111,3,0
1,1,1,-5.5,-4.5,-4.5,WP560,TGF beta receptor signaling,M111,3,0
1,1,1,-5.1,-3.3,-2.9,WP4630,Measles virus infection,M111,3,0
1,1,1,-8.9,-4.7,-2.9,M167,PID AP1 PATHWAY,M111,3,0
1,1,1,-7.3,-5.1,-3.3,GO:0050870,positive regulation of T cell activation,M111,3,0
1,1,1,-6.9,-8.2,-2.4,GO:0046634,regulation of alpha-beta T cell activation,M111,3,0
1,1,1,-5.9,-4,-2.9,GO:0002062,chondrocyte differentiation,M111,3,0
1,1,1,-9.4,-3.7,-5.3,hsa04659,Th17 cell differentiation,M111,3,0
1,1,1,-11,-2.2,-2.3,GO:1902893,regulation of miRNA transcription,M111,3,0
1,1,1,-4,-2.1,-3,GO:0006909,phagocytosis,M111,3,0
1,1,1,-7.9,-6.9,-5.5,WP3945,TYROBP causal network in microglia,M111,3,0
1,1,1,-5,-4.3,-3.7,WP4341,Non genomic actions of 1 25 dihydroxyvitamin D3,M111,3,0
1,1,1,-8.9,-2.2,-3.3,GO:0032774,RNA biosynthetic process,M111,3,0
1,1,1,-5.6,-2.4,-4.2,R-HSA-9679506,SARS-CoV Infections,M111,3,0
1,1,1,-4.3,-3.2,-2.5,GO:0072089,stem cell proliferation,M111,3,0
1,1,1,-8.6,-5.7,-3.6,GO:0045785,positive regulation of cell adhesion,M111,3,0
1,1,1,-6.7,-3.3,-2.1,R-HSA-168898,Toll-like Receptor Cascades,M111,3,0
1,1,1,-19,-15,-9,GO:0030097,hemopoiesis,M111,3,0
1,1,1,-11,-5.1,-5.1,GO:0002683,negative regulation of immune system process,M111,3,0
1,1,1,-3.4,-3.5,-2.4,GO:2000515,"negative regulation of CD4-positive, alpha-beta T cell activation",M111,3,0
1,1,1,-9.8,-5.5,-3.1,hsa05169,Epstein-Barr virus infection,M111,3,0
1,1,1,-3.5,-4.5,-3.5,hsa05142,Chagas disease,M111,3,0
1,1,1,-8.5,-4.5,-3.4,GO:0050867,positive regulation of cell activation,M111,3,0
1,1,1,-9.6,-2.8,-2.8,GO:0070848,response to growth factor,M111,3,0
1,1,1,-9.1,-4.2,-2.7,GO:0045639,positive regulation of myeloid cell differentiation,M111,3,0
1,1,1,-6.5,-5.3,-3.3,hsa05202,Transcriptional misregulation in cancer,M111,3,0
1,1,1,-2.6,-2.2,-2.4,R-HSA-2559583,Cellular Senescence,M111,3,0
1,1,1,-5,-4.9,-2.1,M186,PID PDGFRB PATHWAY,M111,3,0
1,1,1,-2.2,-5.9,-2.4,GO:0050764,regulation of phagocytosis,M111,3,0
1,1,1,-12,-13,-6.1,GO:0002521,leukocyte differentiation,M111,3,0
1,1,1,-4.6,-2.8,-2.9,hsa05162,Measles,M111,3,0
1,1,1,-4.7,-3,-2.1,GO:0045581,negative regulation of T cell differentiation,M111,3,0
1,1,1,-12,-6.9,-3.7,GO:0002694,regulation of leukocyte activation,M111,3,0
1,1,1,-7.4,-4.9,-2.2,GO:0045619,regulation of lymphocyte differentiation,M111,3,0
1,1,1,-11,-2.5,-2.2,GO:0140747,regulation of ncRNA transcription,M111,3,0
1,1,1,-12,-6.8,-2.8,GO:0001819,positive regulation of cytokine production,M111,3,0
1,1,1,-7.6,-7.5,-3.6,WP2849,Hematopoietic stem cell differentiation,M111,3,0
1,1,1,-5.9,-4.1,-3,GO:0051216,cartilage development,M111,3,0
1,1,1,-2.7,-2.6,-4.1,GO:0061515,myeloid cell development,M111,3,0
1,1,1,-12,-7.7,-3.7,GO:0051249,regulation of lymphocyte activation,M111,3,0
1,1,1,-11,-2.5,-2.3,GO:0032103,positive regulation of response to external stimulus,M111,3,0
1,1,1,-4.5,-2.2,-2.5,GO:0051607,defense response to virus,M111,3,0
1,1,1,-3.7,-4,-3,R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,M111,3,0
1,1,1,-5.2,-9.3,-3.9,GO:0002252,immune effector process,M111,3,0
1,1,1,-4.1,-9.1,-4,GO:0002366,leukocyte activation involved in immune response,M111,3,0
1,1,1,-15,-8,-3.5,GO:1903706,regulation of hemopoiesis,M111,3,0
1,1,1,-6.4,-2.8,-4.9,WP2203,Thymic stromal lymphopoietin TSLP signaling pathway,M111,3,0
1,1,1,-7.3,-5.4,-2.4,WP366,TGF beta signaling pathway,M111,3,0
1,1,1,-8.4,-6,-2.5,GO:0001501,skeletal system development,M111,3,0
1,1,1,-4.9,-7,-3.1,GO:0002286,T cell activation involved in immune response,M111,3,0
1,1,1,-6.8,-2.2,-2.7,M54,PID IL12 2PATHWAY,M111,3,0
1,1,1,-8.9,-2.7,-2.6,GO:0045089,positive regulation of innate immune response,M111,3,0
1,1,1,-6.5,-3.1,-2.2,GO:0045596,negative regulation of cell differentiation,M111,3,0
1,1,1,-8.7,-5.2,-2.6,GO:0010720,positive regulation of cell development,M111,3,0
1,1,1,-3.2,-3.2,-2.2,M255,PID HIF1 TFPATHWAY,M111,3,0
1,1,1,-11,-2.1,-4.8,GO:0002831,regulation of response to biotic stimulus,M111,3,0
1,1,1,-11,-4.1,-5.7,hsa05161,Hepatitis B,M111,3,0
1,1,1,-6.2,-2.4,-2.9,WP5083,Neuroinflammation and glutamatergic signaling,M111,3,0
1,1,1,-6.6,-7.5,-3.4,WP286,IL 3 signaling pathway,M111,3,0
1,1,1,-2.7,-2.3,-2.9,R-HSA-9018519,Estrogen-dependent gene expression,M111,3,0
1,1,1,-4.5,-2.2,-2.5,GO:0140546,defense response to symbiont,M111,3,0
1,1,1,-7.1,-4.1,-2.4,GO:0061448,connective tissue development,M111,3,0
1,1,1,-10,-8.5,-2.9,GO:0050863,regulation of T cell activation,M111,3,0
1,1,1,-9.9,-5.6,-3.5,GO:0045637,regulation of myeloid cell differentiation,M111,3,0
1,1,1,-6.8,-3.9,-2.7,GO:0008283,cell population proliferation,M111,3,0
1,1,1,-4.8,-3.5,-2.4,GO:0045621,positive regulation of lymphocyte differentiation,M111,3,0
1,1,1,-13,-6.6,-5.1,R-HSA-449147,Signaling by Interleukins,M111,3,0
1,1,1,-5.7,-4.5,-3.4,GO:0050868,negative regulation of T cell activation,M111,3,0
1,1,1,-9.1,-4.2,-3.4,GO:0019221,cytokine-mediated signaling pathway,M111,3,0
1,1,1,-6.7,-2,-5.4,WP395,IL 4 signaling pathway,M111,3,0
1,1,1,-12,-17,-5.9,GO:0046649,lymphocyte activation,M111,3,0
1,1,1,-6.4,-4.9,-3.3,GO:1903038,negative regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-2.6,-4.1,-2.6,GO:0002861,regulation of inflammatory response to antigenic stimulus,M111,3,0
1,1,1,-11,-8.8,-3.2,GO:0045087,innate immune response,M111,3,0
1,1,1,-7.2,-4.2,-2.4,GO:1903708,positive regulation of hemopoiesis,M111,3,0
1,1,1,-8.9,-2.2,-2.1,GO:1902895,positive regulation of miRNA transcription,M111,3,0
1,1,1,-15,-3.3,-4.1,GO:0031348,negative regulation of defense response,M111,3,0
1,1,1,-4.8,-2,-3,WP3972,PDGFR beta pathway,M111,3,0
1,1,1,-3.8,-2.7,-2.4,GO:0002699,positive regulation of immune effector process,M111,3,0
1,1,1,-6.9,-3.3,-3.4,hsa05203,Viral carcinogenesis,M111,3,0
1,1,1,-4.1,-9.1,-4,GO:0002263,cell activation involved in immune response,M111,3,0
1,1,1,-3.9,-8.6,-4.2,GO:0002285,lymphocyte activation involved in immune response,M111,3,0
1,1,1,-9.3,-2.2,-2.7,WP75,Toll like receptor signaling pathway,M111,3,0
1,1,1,-7,-5.3,-2.5,GO:0030218,erythrocyte differentiation,M111,3,0
1,1,1,-2.6,-4.8,-2.9,GO:0071353,cellular response to interleukin-4,M111,3,0
1,1,1,-3.8,-2.6,-2.8,R-HSA-8878159,Transcriptional regulation by RUNX3,M111,3,0
1,1,1,-3.4,-4.9,-2.6,hsa05221,Acute myeloid leukemia,M111,3,0
1,1,1,-5.1,-3.6,-2.7,hsa05215,Prostate cancer,M111,3,0
1,1,1,-6.2,-4.9,-3.6,WP437,EGF EGFR signaling pathway,M111,3,0
1,1,1,-8.5,-6.1,-2.2,GO:0002757,immune response-activating signaling pathway,M111,3,0
1,1,1,-13,-7,-3.7,GO:0050778,positive regulation of immune response,M111,3,0
1,1,1,-6.8,-4.8,-3.6,GO:0051250,negative regulation of lymphocyte activation,M111,3,0
1,1,1,-7,-4.9,-2.4,GO:0034101,erythrocyte homeostasis,M111,3,0
1,1,1,-4.7,-5.3,-2.3,R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",M111,3,0
1,1,1,-12,-2.7,-4.1,GO:0045088,regulation of innate immune response,M111,3,0
1,1,1,-6.8,-4.9,-3.1,GO:0002695,negative regulation of leukocyte activation,M111,3,0
1,1,1,-4.6,-3.3,-2.7,GO:0043371,"negative regulation of CD4-positive, alpha-beta T cell differentiation",M111,3,0
1,1,1,-3,-4.5,-3.1,GO:0046636,negative regulation of alpha-beta T cell activation,M111,3,0
1,1,1,-5.1,-3.1,-2.2,GO:0009615,response to virus,M111,3,0
1,1,1,-3.9,-2.2,-2.5,M33,PID GLYPICAN 1PATHWAY,M111,3,0
1,1,1,-9.8,-8.4,-7.9,GO:0030099,myeloid cell differentiation,M111,3,0
1,1,1,-4.2,-3.5,-2.4,GO:0046635,positive regulation of alpha-beta T cell activation,M111,3,0
1,1,1,-4.9,-3.5,-4.2,M28,PID IL4 2PATHWAY,M111,3,0
1,1,1,-5.3,-4.4,-4.5,WP4816,TGF beta receptor signaling in skeletal dysplasias,M111,3,0
1,1,1,-6,-3.5,-2.4,WP2018,RANKL RANK signaling pathway,M111,3,0
1,1,1,-14,-16,-7.7,GO:0001775,cell activation,M111,3,0
1,1,1,-8,-5.8,-3.2,GO:0022409,positive regulation of cell-cell adhesion,M111,3,0
1,1,1,-5.8,-4.3,-2,hsa05235,PD-L1 expression and PD-1 checkpoint pathway in cancer,M111,3,0
1,1,1,-3.1,-2.5,-2.8,GO:0002702,positive regulation of production of molecular mediator of immune response,M111,3,0
1,1,1,-4.5,-3.9,-2.9,GO:0032479,regulation of type I interferon production,M111,3,0
1,1,1,-11,-7.9,-3.5,GO:1903037,regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-8.6,-3.5,-3.2,GO:0071559,response to transforming growth factor beta,M111,3,0
1,1,1,-4,-3.3,-2.1,GO:0002700,regulation of production of molecular mediator of immune response,M111,3,0
1,1,1,-3.6,-2.8,-2.4,hsa05220,Chronic myeloid leukemia,M111,3,0
1,1,1,-7.3,-3.6,-5.1,hsa04658,Th1 and Th2 cell differentiation,M111,3,0
1,1,1,-8.1,-5.9,-3.6,GO:1903039,positive regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-3.3,-3.8,-3.4,GO:1903707,negative regulation of hemopoiesis,M111,3,0
1,1,1,-3.8,-3,-3.7,GO:2001187,"positive regulation of CD8-positive, alpha-beta T cell activation",M111,3,0
1,1,1,-6.5,-4.2,-3,GO:0022408,negative regulation of cell-cell adhesion,M111,3,0
1,1,1,-5.5,-2.2,-2.5,WP706,Sudden infant death syndrome SIDS susceptibility pathways,M111,3,0
1,1,1,-3.4,-2.3,-2.2,WP304,Kit receptor signaling pathway,M111,3,0
1,1,1,-3.3,-4.8,-2.6,WP5293,Acute myeloid leukemia,M111,3,0
1,1,1,-12,-3.1,-3.3,M183,PID IL6 7 PATHWAY,M111,3,0
1,1,1,-11,-6.3,-3.1,GO:0050865,regulation of cell activation,M111,3,0
1,1,1,-14,-6.1,-3.6,GO:0071345,cellular response to cytokine stimulus,M111,3,0
1,1,1,-2.8,-2,-3,R-HSA-186763,Downstream signal transduction,M111,3,0
1,1,1,-9.1,-4.5,-3.6,GO:0002696,positive regulation of leukocyte activation,M111,3,0
1,1,1,-7.2,-4.2,-2.4,GO:1902107,positive regulation of leukocyte differentiation,M111,3,0
1,1,1,-9.9,-4.6,-5.8,GO:0050777,negative regulation of immune response,M111,3,0
1,1,1,-11,-9.1,-3.2,hsa04380,Osteoclast differentiation,M111,3,0
1,1,1,-8.5,-2.7,-2.4,GO:0002833,positive regulation of response to biotic stimulus,M111,3,0
1,1,1,-6.2,-2.9,-2.1,GO:0007167,enzyme-linked receptor protein signaling pathway,M111,3,0
1,1,1,-9.1,-2.9,-6.1,WP4666,Hepatitis B infection,M111,3,0
1,1,1,-11,-3.9,-5.3,WP5130,Th17 cell differentiation pathway,M111,3,0
1,1,1,-7.2,-6.9,-2.1,GO:0002768,immune response-regulating cell surface receptor signaling pathway,M111,3,0
1,1,1,-14,-16,-6.8,GO:0045321,leukocyte activation,M111,3,0
1,1,1,-5.5,-5.1,-2.3,GO:0002761,regulation of myeloid leukocyte differentiation,M111,3,0
1,1,1,-8.9,-2,-2.5,GO:0006366,transcription by RNA polymerase II,M111,3,0
1,1,1,-11,-6.4,-3.1,GO:0022407,regulation of cell-cell adhesion,M111,3,0
1,1,1,-10,-12,-4.2,GO:1903131,mononuclear cell differentiation,M111,3,0
1,1,1,-6.8,-2.4,-3.9,WP3858,Toll like receptor signaling related to MyD88,M111,3,0
1,1,1,-3.1,-2.5,-2.9,GO:0032648,regulation of interferon-beta production,M111,3,0
1,1,1,-5,-4.5,-2.1,GO:0002573,myeloid leukocyte differentiation,M111,3,0
1,1,1,-14,-9.9,-6,R-HSA-1280215,Cytokine Signaling in Immune system,M111,3,0
1,1,1,-8.7,-2.3,-3.4,GO:0006351,DNA-templated transcription,M111,3,0
1,1,1,-8.6,-10,-3.9,GO:0030098,lymphocyte differentiation,M111,3,0
1,1,1,-4.4,-2.4,-2.5,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M111,3,0
1,1,1,-9,-4.8,-3.9,GO:0051251,positive regulation of lymphocyte activation,M111,3,0
1,1,1,-3.9,-3,-2.5,GO:0046639,negative regulation of alpha-beta T cell differentiation,M111,3,0
1,1,1,-6.7,-4.3,-2.7,GO:0050866,negative regulation of cell activation,M111,3,0
1,1,1,-5.2,-2.5,-2.5,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,M111,3,0
1,1,1,-11,-3.7,-4.1,hsa05166,Human T-cell leukemia virus 1 infection,M111,3,0
1,1,1,-9.2,-6.4,-4,hsa05200,Pathways in cancer,M111,3,0
1,1,1,-3.9,-4.2,-4.1,R-HSA-9616222,Transcriptional regulation of granulopoiesis,M111,3,0
1,1,1,-11,-7.7,-2.3,GO:1902105,regulation of leukocyte differentiation,M111,3,0
1,1,1,-14,-6.7,-4.1,hsa05167,Kaposi sarcoma-associated herpesvirus infection,M111,3,0
1,1,0,-5.5,-2.7,0,M17200,SA B CELL RECEPTOR COMPLEXES,M110,2,0
1,0,1,-6.5,0,-2.8,GO:0009725,response to hormone,M101,2,0
1,0,1,-3.1,0,-4.7,GO:0035771,interleukin-4-mediated signaling pathway,M101,2,0
1,1,0,-5.4,-4.7,0,R-HSA-9664417,Leishmania phagocytosis,M110,2,0
1,1,0,-4.1,-3.8,0,hsa04935,"Growth hormone synthesis, secretion and action",M110,2,0
1,1,0,-2.3,-2.9,0,R-HSA-76002,"Platelet activation, signaling and aggregation",M110,2,0
1,1,0,-3.6,-3.2,0,M34,PID TCR PATHWAY,M110,2,0
1,1,0,-8.2,-2.5,0,GO:0051345,positive regulation of hydrolase activity,M110,2,0
1,0,1,-4.4,0,-2.7,GO:0045444,fat cell differentiation,M101,2,0
1,1,0,-6.4,-7.5,0,R-HSA-9658195,Leishmania infection,M110,2,0
1,0,1,-4.9,0,-3.3,WP236,Adipogenesis,M101,2,0
1,1,0,-8.5,-5.4,0,GO:0002697,regulation of immune effector process,M110,2,0
1,1,0,-3.7,-2.4,0,GO:0002200,somatic diversification of immune receptors,M110,2,0
1,1,0,-3.4,-3.6,0,GO:0032943,mononuclear cell proliferation,M110,2,0
1,1,0,-2.3,-3.4,0,GO:0038110,interleukin-2-mediated signaling pathway,M110,2,0
1,1,0,-2.3,-2.1,0,GO:0007368,determination of left/right symmetry,M110,2,0
1,1,0,-4.4,-3.5,0,GO:0045582,positive regulation of T cell differentiation,M110,2,0
1,1,0,-4.1,-2.7,0,WP4216,Chromosomal and microsatellite instability in colorectal cancer,M110,2,0
1,1,0,-3.5,-3.3,0,M2,PID SMAD2 3NUCLEAR PATHWAY,M110,2,0
1,0,1,-2.2,0,-3.8,GO:0051091,positive regulation of DNA-binding transcription factor activity,M101,2,0
1,1,0,-2.2,-5.2,0,GO:0030183,B cell differentiation,M110,2,0
1,1,0,-5.2,-2.3,0,GO:0010464,regulation of mesenchymal cell proliferation,M110,2,0
1,1,0,-4.8,-2.4,0,GO:0022612,gland morphogenesis,M110,2,0
1,1,0,-2,-2.2,0,R-HSA-912526,Interleukin receptor SHC signaling,M110,2,0
1,1,0,-5.2,-4.8,0,GO:0043370,"regulation of CD4-positive, alpha-beta T cell differentiation",M110,2,0
1,1,0,-8.1,-2.5,0,GO:0002698,negative regulation of immune effector process,M110,2,0
1,1,0,-2.6,-4.8,0,GO:0038094,Fc-gamma receptor signaling pathway,M110,2,0
1,1,0,-2.2,-3.7,0,GO:2000107,negative regulation of leukocyte apoptotic process,M110,2,0
1,1,0,-2.2,-3.7,0,hsa04730,Long-term depression,M110,2,0
1,1,0,-2.8,-2,0,M63,PID AVB3 OPN PATHWAY,M110,2,0
1,1,0,-5,-5.1,0,R-HSA-109582,Hemostasis,M110,2,0
1,1,0,-2.3,-2.8,0,GO:0071378,cellular response to growth hormone stimulus,M110,2,0
1,1,0,-2.2,-2.8,0,WP4223,Ras signaling,M110,2,0
1,1,0,-6.5,-2,0,GO:0048872,homeostasis of number of cells,M110,2,0
1,1,0,-2.3,-3.5,0,M99,PID TXA2PATHWAY,M110,2,0
1,1,0,-9.4,-7.4,0,WP23,B cell receptor signaling pathway,M110,2,0
1,1,0,-4.6,-3,0,GO:1903557,positive regulation of tumor necrosis factor superfamily cytokine production,M110,2,0
1,1,0,-3.4,-3.6,0,GO:0046651,lymphocyte proliferation,M110,2,0
1,1,0,-3.7,-3.9,0,GO:0002274,myeloid leukocyte activation,M110,2,0
1,1,0,-2.3,-3.4,0,CORUM:2694,ERG-JUN-FOS DNA-protein complex,M110,2,0
1,1,0,-2.4,-2.2,0,R-HSA-9607240,FLT3 Signaling,M110,2,0
1,1,0,-4.2,-2.7,0,GO:0140467,integrated stress response signaling,M110,2,0
1,0,1,-2.5,0,-2.3,GO:2000144,positive regulation of DNA-templated transcription initiation,M101,2,0
1,1,0,-4.2,-2.3,0,R-HSA-9700206,Signaling by ALK in cancer,M110,2,0
1,0,1,-2.8,0,-2.7,WP5272,LDL influence on CD14 and TLR4,M101,2,0
1,1,0,-2.2,-2.3,0,GO:0014015,positive regulation of gliogenesis,M110,2,0
1,1,0,-5.8,-2.3,0,GO:0141091,transforming growth factor beta receptor superfamily signaling pathway,M110,2,0
1,1,0,-4.7,-3.7,0,GO:0002294,"CD4-positive, alpha-beta T cell differentiation involved in immune response",M110,2,0
1,1,0,-2.8,-2.3,0,GO:0046638,positive regulation of alpha-beta T cell differentiation,M110,2,0
1,1,0,-5.9,-3,0,GO:0007389,pattern specification process,M110,2,0
1,1,0,-4.5,-2,0,GO:0032677,regulation of interleukin-8 production,M110,2,0
1,1,0,-2,-2.5,0,GO:0038096,Fc-gamma receptor signaling pathway involved in phagocytosis,M110,2,0
1,1,0,-3.2,-2.2,0,GO:0007224,smoothened signaling pathway,M110,2,0
1,1,0,-2,-2.2,0,GO:0035723,interleukin-15-mediated signaling pathway,M110,2,0
1,1,0,-2.3,-4.3,0,GO:0051098,regulation of binding,M110,2,0
1,1,0,-5,-6.9,0,hsa04650,Natural killer cell mediated cytotoxicity,M110,2,0
1,1,0,-7.1,-4.5,0,GO:0032944,regulation of mononuclear cell proliferation,M110,2,0
1,0,1,-6,0,-3.8,R-HSA-9824446,Viral Infection Pathways,M101,2,0
0,1,1,0,-4.7,-2.5,GO:0016064,immunoglobulin mediated immune response,M011,2,0
0,1,1,0,-2,-3,GO:0046847,filopodium assembly,M011,2,0
1,1,0,-4.9,-6.1,0,GO:2000514,"regulation of CD4-positive, alpha-beta T cell activation",M110,2,0
1,1,0,-2,-2.2,0,GO:0071350,cellular response to interleukin-15,M110,2,0
1,1,0,-3.4,-3.7,0,hsa05140,Leishmaniasis,M110,2,0
1,1,0,-6.7,-4.4,0,GO:0070663,regulation of leukocyte proliferation,M110,2,0
1,1,0,-8.2,-5.7,0,GO:0001818,negative regulation of cytokine production,M110,2,0
1,1,0,-7.1,-4.5,0,WP5072,Modulators of TCR signaling and T cell activation,M110,2,0
1,0,1,-4.5,0,-3.2,M115,PID REG GR PATHWAY,M101,2,0
1,0,1,-11,0,-2.9,GO:2000628,regulation of miRNA metabolic process,M101,2,0
1,1,0,-3.7,-4,0,R-HSA-912631,Regulation of signaling by CBL,M110,2,0
1,1,0,-2.3,-3.4,0,GO:0071352,cellular response to interleukin-2,M110,2,0
1,1,0,-6.5,-2.4,0,GO:0051336,regulation of hydrolase activity,M110,2,0
1,1,0,-6,-2.9,0,hsa05170,Human immunodeficiency virus 1 infection,M110,2,0
1,1,0,-6.1,-2.9,0,GO:0061061,muscle structure development,M110,2,0
1,1,0,-11,-3,0,GO:0050728,negative regulation of inflammatory response,M110,2,0
1,1,0,-5.6,-3.1,0,hsa05207,Chemical carcinogenesis - receptor activation,M110,2,0
1,1,0,-4.5,-3.6,0,GO:0002293,alpha-beta T cell differentiation involved in immune response,M110,2,0
1,1,0,-5.2,-2,0,GO:0032663,regulation of interleukin-2 production,M110,2,0
1,1,0,-3.6,-3.1,0,hsa05225,Hepatocellular carcinoma,M110,2,0
1,1,0,-5.2,-2.5,0,GO:0002823,negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M110,2,0
1,1,0,-2.9,-3.2,0,GO:0046640,regulation of alpha-beta T cell proliferation,M110,2,0
1,0,1,-3.1,0,-2.3,GO:0002637,regulation of immunoglobulin production,M101,2,0
1,1,0,-2.8,-2,0,GO:0060251,regulation of glial cell proliferation,M110,2,0
1,1,0,-4.9,-2.6,0,GO:0072091,regulation of stem cell proliferation,M110,2,0
1,1,0,-2.6,-2.3,0,GO:1903306,negative regulation of regulated secretory pathway,M110,2,0
1,1,0,-2.1,-2.4,0,GO:0043304,regulation of mast cell degranulation,M110,2,0
1,1,0,-8.3,-6.8,0,R-HSA-1280218,Adaptive Immune System,M110,2,0
1,0,1,-2.3,0,-2,GO:0043255,regulation of carbohydrate biosynthetic process,M101,2,0
1,1,0,-2.5,-5.1,0,R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,M110,2,0
1,1,0,-7.3,-2.9,0,GO:0042129,regulation of T cell proliferation,M110,2,0
1,0,1,-6.5,0,-2.3,GO:0071216,cellular response to biotic stimulus,M101,2,0
1,0,1,-2.5,0,-2.9,GO:0007249,canonical NF-kappaB signal transduction,M101,2,0
1,1,0,-2.6,-3.2,0,hsa05135,Yersinia infection,M110,2,0
1,0,1,-6.4,0,-2.4,GO:0050678,regulation of epithelial cell proliferation,M101,2,0
1,1,0,-3.1,-2.8,0,GO:0071355,cellular response to interleukin-9,M110,2,0
1,1,0,-3.9,-5.6,0,GO:0051101,regulation of DNA binding,M110,2,0
1,0,1,-4.5,0,-2.4,WP3594,Circadian rhythm genes,M101,2,0
1,0,1,-2.1,0,-2.2,R-HSA-1834949,Cytosolic sensors of pathogen-associated DNA,M101,2,0
1,1,0,-2,-2.2,0,GO:0060395,SMAD protein signal transduction,M110,2,0
1,0,1,-4.2,0,-2.4,WP5353,A network map of Macrophage stimulating protein MSP signaling,M101,2,0
1,1,0,-2.4,-2.4,0,CORUM:1372,Rb-tal-1-E2A-Lmo2-Ldb1 complex,M110,2,0
1,1,0,-2,-2.2,0,R-HSA-164952,The role of Nef in HIV-1 replication and disease pathogenesis,M110,2,0
1,1,0,-3.2,-6.7,0,WP3937,Microglia pathogen phagocytosis pathway,M110,2,0
1,1,0,-2.4,-2.4,0,hsa05130,Pathogenic Escherichia coli infection,M110,2,0
1,1,0,-11,-3.6,0,GO:0050727,regulation of inflammatory response,M110,2,0
1,1,0,-3.7,-2,0,WP313,Hepatocyte growth factor receptor signaling,M110,2,0
1,1,0,-5.6,-2,0,GO:0070664,negative regulation of leukocyte proliferation,M110,2,0
1,1,0,-3.1,-2.2,0,GO:0002862,negative regulation of inflammatory response to antigenic stimulus,M110,2,0
1,1,0,-3.2,-2.3,0,GO:0002709,regulation of T cell mediated immunity,M110,2,0
1,1,0,-5.1,-4.7,0,M124,PID CXCR4 PATHWAY,M110,2,0
1,1,0,-6.3,-3.7,0,hsa05152,Tuberculosis,M110,2,0
1,1,0,-7.4,-3.5,0,M290,PID IL12 STAT4 PATHWAY,M110,2,0
1,1,0,-3.6,-2.1,0,M141,PID PI3KCI PATHWAY,M110,2,0
1,1,0,-4.7,-6.4,0,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,M110,2,0
1,1,0,-2.9,-2.1,0,GO:0043388,positive regulation of DNA binding,M110,2,0
1,1,0,-2.8,-2,0,GO:0021781,glial cell fate commitment,M110,2,0
1,1,0,-7.9,-3.4,0,hsa05417,Lipid and atherosclerosis,M110,2,0
1,1,0,-5.6,-2.4,0,R-HSA-8980692,RHOA GTPase cycle,M110,2,0
1,1,0,-4.7,-4.8,0,GO:0035710,"CD4-positive, alpha-beta T cell activation",M110,2,0
1,1,0,-2.4,-2.4,0,R-HSA-202403,TCR signaling,M110,2,0
1,1,0,-4.1,-3.1,0,GO:1903305,regulation of regulated secretory pathway,M110,2,0
1,1,0,-2.2,-2.1,0,GO:0032507,maintenance of protein location in cell,M110,2,0
1,1,0,-5.7,-2.4,0,WP231,TNF alpha signaling pathway,M110,2,0
1,1,0,-5.9,-4.6,0,GO:0002460,adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M110,2,0
1,1,0,-2.5,-5.1,0,R-HSA-9664433,Leishmania parasite growth and survival,M110,2,0
1,1,0,-5.4,-4.6,0,R-HSA-9012999,RHO GTPase cycle,M110,2,0
1,1,0,-2.1,-2,0,GO:0003416,endochondral bone growth,M110,2,0
1,1,0,-6.9,-4.2,0,GO:0050670,regulation of lymphocyte proliferation,M110,2,0
1,1,0,-2.8,-2,0,GO:0060443,mammary gland morphogenesis,M110,2,0
1,0,1,-3.4,0,-4.5,M285,PID HNF3A PATHWAY,M101,2,0
1,0,1,-9.1,0,-3,GO:0009617,response to bacterium,M101,2,0
1,1,0,-7.7,-2,0,WP2374,Oncostatin M signaling pathway,M110,2,0
1,1,0,-4.1,-2.1,0,GO:0043068,positive regulation of programmed cell death,M110,2,0
1,1,0,-4.8,-2.2,0,GO:0051046,regulation of secretion,M110,2,0
1,1,0,-5.3,-2.2,0,WP49,IL 2 signaling pathway,M110,2,0
1,0,1,-4.4,0,-3.3,GO:0045824,negative regulation of innate immune response,M101,2,0
1,1,0,-2.6,-2.3,0,M252,PID IL8 CXCR1 PATHWAY,M110,2,0
1,1,0,-4.7,-2.6,0,GO:0002706,regulation of lymphocyte mediated immunity,M110,2,0
1,1,0,-9.4,-3.7,0,GO:0002704,negative regulation of leukocyte mediated immunity,M110,2,0
1,0,1,-3.1,0,-3.1,R-HSA-8853884,Transcriptional Regulation by VENTX,M101,2,0
1,0,1,-11,0,-2.4,GO:0032102,negative regulation of response to external stimulus,M101,2,0
1,1,0,-3.3,-4.1,0,WP4262,Breast cancer pathway,M110,2,0
1,1,0,-4.7,-6,0,M7,PID FCER1 PATHWAY,M110,2,0
1,0,1,-3.1,0,-2.5,R-HSA-5602358,Diseases associated with the TLR signaling cascade,M101,2,0
1,0,1,-2.8,0,-3,GO:0045063,T-helper 1 cell differentiation,M101,2,0
1,1,0,-2.8,-2.4,0,R-HSA-909733,Interferon alpha/beta signaling,M110,2,0
1,1,0,-3.8,-6.2,0,hsa04666,Fc gamma R-mediated phagocytosis,M110,2,0
1,1,0,-6.8,-4,0,WP5218,Extrafollicular and follicular B cell activation by SARS CoV 2,M110,2,0
1,1,0,-3.2,-2.2,0,GO:0042116,macrophage activation,M110,2,0
1,1,0,-4.8,-3.8,0,R-HSA-5621481,C-type lectin receptors (CLRs),M110,2,0
1,1,0,-3.1,-2,0,R-HSA-166520,Signaling by NTRKs,M110,2,0
1,1,0,-3.7,-2.8,0,GO:0045622,regulation of T-helper cell differentiation,M110,2,0
1,1,0,-2,-2.2,0,GO:0002887,negative regulation of myeloid leukocyte mediated immunity,M110,2,0
1,1,0,-7.9,-6.8,0,hsa04660,T cell receptor signaling pathway,M110,2,0
1,1,0,-2.3,-2.2,0,CORUM:5232,"TNF-alpha/Nf-kappa B signaling complex (RPL6, RPL30, RPS13, CHUK, DDX3X, NFKB2, NFKBIB, REL, IKBKG, NFKB1, MAP3K8, RELB, GLG1, NFKBIA, RELA, TNIP2,  GTF2I)",M110,2,0
1,1,0,-3.5,-2.3,0,GO:0048821,erythrocyte development,M110,2,0
1,1,0,-2.4,-2.4,0,CORUM:2084,NFKB1-NFKB2-REL-RELA-RELB complex,M110,2,0
1,0,1,-2.5,0,-2.4,R-HSA-9694516,SARS-CoV-2 Infection,M101,2,0
1,1,0,-5.5,-3.1,0,GO:0050900,leukocyte migration,M110,2,0
1,1,0,-4.6,-2.2,0,GO:0060333,type II interferon-mediated signaling pathway,M110,2,0
1,1,0,-2.6,-2.3,0,GO:0021846,cell proliferation in forebrain,M110,2,0
1,1,0,-6.3,-2.3,0,WP4149,White fat cell differentiation,M110,2,0
1,0,1,-2.8,0,-2.7,GO:0002639,positive regulation of immunoglobulin production,M101,2,0
1,1,0,-4.4,-3.7,0,M22,PID GMCSF PATHWAY,M110,2,0
1,1,0,-3.8,-4.4,0,GO:0002886,regulation of myeloid leukocyte mediated immunity,M110,2,0
1,0,1,-3.6,0,-2.8,R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,M101,2,0
1,1,0,-3.7,-2,0,GO:0030335,positive regulation of cell migration,M110,2,0
1,1,0,-6.2,-2.6,0,WP2840,Hair follicle development cytodifferentiation part 3 of 3,M110,2,0
1,1,0,-3.3,-2.9,0,R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,M110,2,0
1,0,1,-2.8,0,-2,GO:2000142,regulation of DNA-templated transcription initiation,M101,2,0
0,1,1,0,-3.1,-2.2,GO:0002312,B cell activation involved in immune response,M011,2,0
1,1,0,-3.4,-2.3,0,GO:0045682,regulation of epidermis development,M110,2,0
1,1,0,-6.5,-3.4,0,GO:0002262,myeloid cell homeostasis,M110,2,0
1,1,0,-2.3,-3.4,0,CORUM:2693,NFAT-JUN-FOS DNA-protein complex,M110,2,0
1,1,0,-6.5,-2.5,0,GO:0035239,tube morphogenesis,M110,2,0
1,1,0,-4.3,-3.5,0,GO:0002292,T cell differentiation involved in immune response,M110,2,0
1,1,0,-2.1,-3.3,0,M1315,SIG PIP3 SIGNALING IN B LYMPHOCYTES,M110,2,0
1,1,0,-2.4,-2.4,0,R-HSA-8985947,Interleukin-9 signaling,M110,2,0
1,1,0,-8.7,-4.4,0,WP69,T cell receptor signaling pathway,M110,2,0
1,1,0,-4.2,-5.5,0,M8626,SIG BCR SIGNALING PATHWAY,M110,2,0
1,0,1,-5.2,0,-2.6,GO:0042088,T-helper 1 type immune response,M101,2,0
1,0,1,-3.4,0,-2.6,WP2795,Cardiac hypertrophic response,M101,2,0
1,1,0,-3.9,-4.1,0,R-HSA-9013149,RAC1 GTPase cycle,M110,2,0
1,1,0,-3.1,-2.2,0,GO:0060438,trachea development,M110,2,0
1,1,0,-6.3,-3,0,WP5098,T cell activation SARS CoV 2,M110,2,0
1,1,0,-4.2,-2.4,0,GO:0030879,mammary gland development,M110,2,0
1,0,1,-6,0,-3.2,WP5422,IL 19 signaling pathway map,M101,2,0
1,1,0,-3.6,-2.8,0,R-HSA-451927,Interleukin-2 family signaling,M110,2,0
1,1,0,-3.2,-2,0,WP254,Apoptosis,M110,2,0
1,1,0,-2.3,-2.8,0,GO:0060396,growth hormone receptor signaling pathway,M110,2,0
1,1,0,-3.7,-5.1,0,R-HSA-2871796,FCERI mediated MAPK activation,M110,2,0
1,0,1,-9.1,0,-5.8,WP5198,Inflammatory bowel disease signaling,M101,2,0
1,1,0,-2.3,-4,0,GO:0046645,positive regulation of gamma-delta T cell activation,M110,2,0
1,0,1,-4.8,0,-2.7,GO:1901652,response to peptide,M101,2,0
1,1,0,-2.3,-3.4,0,CORUM:2695,ETS2-FOS-JUN complex,M110,2,0
1,1,0,-3.9,-2.2,0,R-HSA-1433557,Signaling by SCF-KIT,M110,2,0
1,1,0,-3,-2.2,0,WP481,Insulin signaling,M110,2,0
1,1,0,-8.8,-6,0,GO:0002253,activation of immune response,M110,2,0
1,1,0,-2,-2.7,0,GO:0050869,negative regulation of B cell activation,M110,2,0
1,1,0,-2.5,-2.6,0,R-HSA-4086398,Ca2+ pathway,M110,2,0
1,1,0,-4,-5.7,0,hsa04664,Fc epsilon RI signaling pathway,M110,2,0
1,1,0,-11,-2.3,0,GO:0048568,embryonic organ development,M110,2,0
1,0,1,-5.6,0,-2.4,GO:0002758,innate immune response-activating signaling pathway,M101,2,0
1,1,0,-2.9,-2.4,0,GO:0001837,epithelial to mesenchymal transition,M110,2,0
1,1,0,-4.7,-2.3,0,hsa04062,Chemokine signaling pathway,M110,2,0
1,1,0,-2.4,-2.4,0,GO:0001915,negative regulation of T cell mediated cytotoxicity,M110,2,0
1,1,0,-5.2,-2.9,0,R-HSA-5607764,CLEC7A (Dectin-1) signaling,M110,2,0
1,0,1,-3.6,0,-2.8,R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,M101,2,0
1,1,0,-2.9,-2.9,0,R-HSA-913531,Interferon Signaling,M110,2,0
1,1,0,-3,-2.4,0,GO:0071277,cellular response to calcium ion,M110,2,0
1,0,1,-4.3,0,-2.7,WP2324,AGE RAGE pathway,M101,2,0
1,1,0,-5.4,-4.7,0,R-HSA-9664407,Parasite infection,M110,2,0
1,1,0,-3.7,-2.1,0,GO:0007498,mesoderm development,M110,2,0
1,1,0,-3.1,-2.2,0,GO:0043313,regulation of neutrophil degranulation,M110,2,0
1,0,1,-4,0,-5.6,hsa04630,JAK-STAT signaling pathway,M101,2,0
1,1,0,-8.1,-3,0,WP5373,Role of hypoxia angiogenesis and FGF pathway in OA chondrocyte hypertrophy,M110,2,0
1,1,0,-2.6,-4.3,0,GO:0060348,bone development,M110,2,0
1,1,0,-4.9,-2.1,0,WP2882,Nuclear receptors meta pathway,M110,2,0
1,0,1,-4.2,0,-3.3,WP5362,TAR syndrome,M101,2,0
1,1,0,-2.4,-2.4,0,R-HSA-9027284,Erythropoietin activates RAS,M110,2,0
1,1,0,-2,-2.5,0,GO:0002433,immune response-regulating cell surface receptor signaling pathway involved in phagocytosis,M110,2,0
1,1,0,-2.4,-2.2,0,GO:0032743,positive regulation of interleukin-2 production,M110,2,0
1,0,1,-3.1,0,-2.5,R-HSA-5260271,Diseases of Immune System,M101,2,0
1,1,0,-2.3,-3.2,0,WP4304,Oligodendrocyte specification and differentiation leading to myelin components for CNS,M110,2,0
1,1,0,-3.1,-3.1,0,WP2023,Cell differentiation expanded index,M110,2,0
1,1,0,-2.3,-2.8,0,GO:0043301,negative regulation of leukocyte degranulation,M110,2,0
1,0,1,-2.1,0,-3.5,WP5224,2q37 copy number variation syndrome,M101,2,0
1,1,0,-5.2,-3.5,0,GO:0003002,regionalization,M110,2,0
1,1,0,-8.3,-2.6,0,GO:0045646,regulation of erythrocyte differentiation,M110,2,0
1,1,0,-8.1,-6.8,0,GO:0030217,T cell differentiation,M110,2,0
1,0,1,-6.1,0,-4.1,GO:0061351,neural precursor cell proliferation,M101,2,0
0,1,1,0,-2.3,-2.2,GO:0006468,protein phosphorylation,M011,2,0
1,1,0,-4,-3,0,GO:0002763,positive regulation of myeloid leukocyte differentiation,M110,2,0
1,1,0,-4.7,-2.7,0,GO:0007423,sensory organ development,M110,2,0
1,1,0,-4,-3.6,0,GO:0050731,positive regulation of peptidyl-tyrosine phosphorylation,M110,2,0
1,0,1,-5.3,0,-3.6,GO:0051090,regulation of DNA-binding transcription factor activity,M101,2,0
1,0,1,-3.7,0,-2.2,R-HSA-8939211,ESR-mediated signaling,M101,2,0
1,1,0,-3.6,-2.2,0,R-HSA-194138,Signaling by VEGF,M110,2,0
1,0,1,-2.2,0,-3.3,WP2380,Brain derived neurotrophic factor BDNF signaling pathway,M101,2,0
1,1,0,-2.9,-2.1,0,GO:0021700,developmental maturation,M110,2,0
1,1,0,-3.6,-2.3,0,GO:0048469,cell maturation,M110,2,0
1,1,0,-3,-2.4,0,GO:0050871,positive regulation of B cell activation,M110,2,0
1,1,0,-2.4,-2.4,0,GO:0043378,"positive regulation of CD8-positive, alpha-beta T cell differentiation",M110,2,0
1,1,0,-5,-3.9,0,GO:0043367,"CD4-positive, alpha-beta T cell differentiation",M110,2,0
1,0,1,-3.6,0,-2.8,R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,M101,2,0
1,1,0,-2.7,-2,0,WP4879,Overlap between signal transduction pathways contributing to LMNA laminopathies,M110,2,0
1,1,0,-5.8,-2.2,0,GO:0045648,positive regulation of erythrocyte differentiation,M110,2,0
1,1,0,-2.1,-2.9,0,M210,PID IL8 CXCR2 PATHWAY,M110,2,0
1,1,0,-2.2,-2.1,0,R-HSA-8940973,RUNX2 regulates osteoblast differentiation,M110,2,0
1,1,0,-2.4,-3.8,0,WP4255,Non small cell lung cancer,M110,2,0
1,1,0,-5.7,-3.1,0,GO:0002820,negative regulation of adaptive immune response,M110,2,0
1,0,1,-2.1,0,-2.7,M45,PID CD40 PATHWAY,M101,2,0
1,1,0,-6.4,-7.5,0,R-HSA-9824443,Parasitic Infection Pathways,M110,2,0
1,1,0,-2.8,-2.4,0,GO:0002063,chondrocyte development,M110,2,0
1,1,0,-5.3,-4.3,0,GO:0002822,regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M110,2,0
1,1,0,-7.2,-2.1,0,GO:0048598,embryonic morphogenesis,M110,2,0
1,1,0,-4.2,-4.1,0,M88,PID CD8 TCR PATHWAY,M110,2,0
1,1,0,-2.2,-2,0,GO:0060972,left/right pattern formation,M110,2,0
1,0,1,-2,0,-3,GO:0048663,neuron fate commitment,M101,2,0
1,1,0,-11,-6.2,0,GO:0006954,inflammatory response,M110,2,0
1,1,0,-4.6,-2.3,0,M235,PID TCR CALCIUM PATHWAY,M110,2,0
1,0,1,-4.4,0,-2.1,WP5039,SARS CoV 2 innate immunity evasion and cell specific immune response,M101,2,0
1,1,0,-4.4,-2.1,0,GO:2000648,positive regulation of stem cell proliferation,M110,2,0
1,1,0,-7.4,-3.1,0,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M110,2,0
1,1,0,-2.9,-2.7,0,GO:0071695,anatomical structure maturation,M110,2,0
1,1,0,-2.7,-2,0,hsa05212,Pancreatic cancer,M110,2,0
1,1,0,-2.4,-4.8,0,hsa04613,Neutrophil extracellular trap formation,M110,2,0
1,1,0,-6.9,-5.8,0,GO:0002429,immune response-activating cell surface receptor signaling pathway,M110,2,0
1,1,0,-3.5,-4.2,0,hsa05224,Breast cancer,M110,2,0
1,0,1,-3.4,0,-2.2,M195,PID CMYB PATHWAY,M101,2,0
1,1,0,-4.2,-3.1,0,GO:0032760,positive regulation of tumor necrosis factor production,M110,2,0
1,0,1,-3.6,0,-2.9,GO:0043434,response to peptide hormone,M101,2,0
1,1,0,-7.9,-3.3,0,GO:0001701,in utero embryonic development,M110,2,0
1,1,0,-2.1,-2,0,GO:0042832,defense response to protozoan,M110,2,0
1,1,0,-2.3,-2,0,GO:0060840,artery development,M110,2,0
1,1,0,-2.3,-3.5,0,GO:2000106,regulation of leukocyte apoptotic process,M110,2,0
1,0,1,-4.2,0,-2,WP3995,Prion disease pathway,M101,2,0
1,1,0,-7.5,-7.4,0,GO:0046631,alpha-beta T cell activation,M110,2,0
1,1,0,-4.1,-3.6,0,GO:0050730,regulation of peptidyl-tyrosine phosphorylation,M110,2,0
1,1,0,-6.4,-3.7,0,WP3863,T cell antigen receptor TCR pathway during Staphylococcus aureus infection,M110,2,0
1,1,0,-4.1,-2.4,0,WP2857,Mesodermal commitment pathway,M110,2,0
1,1,0,-5.3,-2.1,0,WP5115,Network map of SARS CoV 2 signaling pathway,M110,2,0
1,1,0,-4,-3.7,0,GO:0042098,T cell proliferation,M110,2,0
1,1,0,-11,-2.1,0,GO:0043009,chordate embryonic development,M110,2,0
1,1,0,-3.6,-2.5,0,hsa04145,Phagosome,M110,2,0
1,1,0,-4.4,-5.1,0,GO:0050851,antigen receptor-mediated signaling pathway,M110,2,0
1,1,0,-3.9,-3.4,0,GO:0045058,T cell selection,M110,2,0
1,1,0,-3.5,-2.4,0,GO:0045620,negative regulation of lymphocyte differentiation,M110,2,0
1,0,1,-2.1,0,-3,M151,PID AR TF PATHWAY,M101,2,0
1,1,0,-3.6,-2.1,0,GO:2000147,positive regulation of cell motility,M110,2,0
1,1,0,-3.3,-2,0,GO:0006897,endocytosis,M110,2,0
1,1,0,-2,-2.2,0,M213,PID AR NONGENOMIC PATHWAY,M110,2,0
1,1,0,-3.9,-4.1,0,GO:0070665,positive regulation of leukocyte proliferation,M110,2,0
1,1,0,-4.8,-4.5,0,R-HSA-983705,Signaling by the B Cell Receptor (BCR),M110,2,0
1,1,0,-9.3,-7.4,0,GO:0002250,adaptive immune response,M110,2,0
1,1,0,-3.3,-2.8,0,M268,PID S1P S1P2 PATHWAY,M110,2,0
1,1,0,-3.9,-2.6,0,hsa05210,Colorectal cancer,M110,2,0
1,1,0,-3.1,-3.4,0,GO:0060397,growth hormone receptor signaling pathway via JAK-STAT,M110,2,0
1,1,0,-3.5,-2.3,0,WP1528,Physiological and pathological hypertrophy of the heart,M110,2,0
1,1,0,-3.4,-2.4,0,R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",M110,2,0
1,1,0,-2.2,-2.1,0,M91,PID TCPTP PATHWAY,M110,2,0
1,1,0,-4.7,-3,0,R-HSA-9679191,Potential therapeutics for SARS,M110,2,0
1,1,0,-7,-4.9,0,GO:0002819,regulation of adaptive immune response,M110,2,0
1,0,1,-2.1,0,-3.1,GO:0045638,negative regulation of myeloid cell differentiation,M101,2,0
1,1,0,-6.3,-2.3,0,WP2526,PDGF pathway,M110,2,0
1,1,0,-2,-2.2,0,WP4146,Macrophage markers,M110,2,0
1,1,0,-7.8,-3.1,0,GO:0071560,cellular response to transforming growth factor beta stimulus,M110,2,0
1,1,0,-7.7,-2.9,0,GO:0071363,cellular response to growth factor stimulus,M110,2,0
1,1,0,-4,-2.4,0,R-HSA-187037,Signaling by NTRK1 (TRKA),M110,2,0
1,1,0,-3.4,-2.7,0,GO:0046641,positive regulation of alpha-beta T cell proliferation,M110,2,0
1,1,0,-7.1,-5.6,0,GO:0045580,regulation of T cell differentiation,M110,2,0
1,1,0,-3,-2.1,0,GO:0042531,positive regulation of tyrosine phosphorylation of STAT protein,M110,2,0
1,1,0,-6.5,-2.1,0,WP4217,Ebola virus infection in host,M110,2,0
1,1,0,-4.7,-4.4,0,hsa04928,"Parathyroid hormone synthesis, secretion and action",M110,2,0
1,1,0,-3.5,-2.1,0,GO:0048880,sensory system development,M110,2,0
1,1,0,-2.6,-3.9,0,GO:0070661,leukocyte proliferation,M110,2,0
0,1,1,0,-4.5,-2.5,GO:0019724,B cell mediated immunity,M011,2,0
1,0,1,-2.6,0,-2.5,R-HSA-9705671,SARS-CoV-2 activates/modulates innate and adaptive immune responses,M101,2,0
1,1,0,-5.7,-2.7,0,GO:1903555,regulation of tumor necrosis factor superfamily cytokine production,M110,2,0
1,1,0,-3.2,-2.2,0,GO:0071621,granulocyte chemotaxis,M110,2,0
1,1,0,-5.1,-2.8,0,GO:0051056,regulation of small GTPase mediated signal transduction,M110,2,0
1,1,0,-3.1,-2,0,GO:0043547,positive regulation of GTPase activity,M110,2,0
1,1,0,-3.8,-2.1,0,GO:0042102,positive regulation of T cell proliferation,M110,2,0
1,1,0,-2.9,-6.4,0,R-HSA-2029481,FCGR activation,M110,2,0
1,1,0,-2.2,-2.3,0,WP2880,Glucocorticoid receptor pathway,M110,2,0
1,1,0,-4.4,-3.6,0,GO:0043300,regulation of leukocyte degranulation,M110,2,0
1,1,0,-3.6,-2.2,0,GO:0150063,visual system development,M110,2,0
1,0,1,-2.3,0,-2.8,R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,M101,2,0
1,1,0,-4.1,-3.8,0,WP3527,Pre implantation embryo,M110,2,0
1,0,1,-2.4,0,-2.3,hsa04217,Necroptosis,M101,2,0
1,1,0,-3.1,-2.2,0,GO:0030851,granulocyte differentiation,M110,2,0
1,1,0,-5.2,-2.6,0,GO:0048729,tissue morphogenesis,M110,2,0
1,1,0,-2.9,-2.2,0,R-HSA-202733,Cell surface interactions at the vascular wall,M110,2,0
1,1,0,-3.1,-2.2,0,GO:0045623,negative regulation of T-helper cell differentiation,M110,2,0
1,1,0,-10,-2.2,0,hsa05163,Human cytomegalovirus infection,M110,2,0
1,1,0,-5.6,-5.7,0,GO:0046637,regulation of alpha-beta T cell differentiation,M110,2,0
1,1,0,-2.7,-2.3,0,GO:0034341,response to type II interferon,M110,2,0
1,0,1,-6.1,0,-2.1,GO:0002237,response to molecule of bacterial origin,M101,2,0
1,1,0,-8.4,-2.9,0,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M110,2,0
1,0,1,-4,0,-2.8,WP2036,TNF related weak inducer of apoptosis TWEAK signaling pathway,M101,2,0
1,1,0,-4.2,-2.3,0,R-HSA-9725370,Signaling by ALK fusions and activated point mutants,M110,2,0
1,1,0,-2.1,-3.3,0,WP4205,MET in type 1 papillary renal cell carcinoma,M110,2,0
1,1,0,-2.3,-4.2,0,R-HSA-9006335,Signaling by Erythropoietin,M110,2,0
1,1,0,-3.1,-4.9,0,R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,M110,2,0
1,0,1,-4.3,0,-3.7,GO:0002832,negative regulation of response to biotic stimulus,M101,2,0
1,1,0,-3.6,-3.3,0,GO:0032946,positive regulation of mononuclear cell proliferation,M110,2,0
1,1,0,-3.4,-2.7,0,GO:0007179,transforming growth factor beta receptor signaling pathway,M110,2,0
1,1,0,-5.3,-2,0,WP3929,Chemokine signaling pathway,M110,2,0
1,0,1,-8.3,0,-2.7,GO:2000630,positive regulation of miRNA metabolic process,M101,2,0
1,0,1,-3.6,0,-2.8,R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,M101,2,0
1,1,0,-3.1,-3.1,0,WP3892,Development of pulmonary dendritic cells and macrophage subsets,M110,2,0
1,1,0,-4.5,-3.7,0,R-HSA-2871809,FCERI mediated Ca+2 mobilization,M110,2,0
1,1,0,-4.9,-4.7,0,M10,PID BCR 5PATHWAY,M110,2,0
1,1,0,-3.7,-2.5,0,WP3646,Hepatitis C and hepatocellular carcinoma,M110,2,0
1,1,0,-2.9,-2.8,0,GO:0032733,positive regulation of interleukin-10 production,M110,2,0
1,1,0,-2.8,-2,0,R-HSA-2424491,DAP12 signaling,M110,2,0
1,1,0,-3.3,-2.8,0,R-HSA-8951430,RUNX3 regulates WNT signaling,M110,2,0
1,0,1,-5.2,0,-2.1,WP2037,Prolactin signaling pathway,M101,2,0
1,1,0,-3.1,-2.8,0,GO:0038113,interleukin-9-mediated signaling pathway,M110,2,0
1,0,1,-4,0,-2.8,WP4559,Interactions between immune cells and microRNAs in tumor microenvironment,M101,2,0
1,1,0,-3.3,-2.9,0,GO:0050671,positive regulation of lymphocyte proliferation,M110,2,0
1,0,1,-4,0,-2.8,WP4880,Host pathogen interaction of human coronaviruses interferon induction,M101,2,0
1,1,0,-3.9,-3,0,R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,M110,2,0
1,1,0,-6.1,-2.6,0,WP127,IL 5 signaling pathway,M110,2,0
1,1,0,-3,-2.5,0,GO:0043087,regulation of GTPase activity,M110,2,0
1,1,0,-2.6,-2.7,0,M278,PID RAC1 PATHWAY,M110,2,0
1,1,0,-8.2,-5.3,0,GO:0002703,regulation of leukocyte mediated immunity,M110,2,0
1,1,0,-5.4,-2.8,0,M272,PID CD8 TCR DOWNSTREAM PATHWAY,M110,2,0
1,1,0,-4.9,-2.2,0,hsa04218,Cellular senescence,M110,2,0
1,1,0,-3.8,-3,0,R-HSA-4411364,Binding of TCF/LEF:CTNNB1 to target gene promoters,M110,2,0
1,1,0,-3.4,-2.3,0,WP4674,Head and neck squamous cell carcinoma,M110,2,0
1,1,0,-3.4,-2.5,0,R-HSA-194315,Signaling by Rho GTPases,M110,2,0
1,1,0,-3.1,-2.8,0,GO:0071104,response to interleukin-9,M110,2,0
0,1,1,0,-2.1,-2.4,GO:0032735,positive regulation of interleukin-12 production,M011,2,0
0,1,1,0,-3.1,-2.6,GO:0097028,dendritic cell differentiation,M011,2,0
1,0,1,-3.3,0,-5.2,WP3877,MYD88 distinct input output pathway,M101,2,0
1,0,1,-3.4,0,-2.9,WP4585,Cancer immunotherapy by PD 1 blockade,M101,2,0
1,1,0,-7.1,-2.3,0,GO:0032675,regulation of interleukin-6 production,M110,2,0
1,1,0,-2.6,-4.1,0,R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,M110,2,0
1,1,0,-2.4,-2.1,0,GO:0033077,T cell differentiation in thymus,M110,2,0
1,1,0,-3.7,-2.6,0,GO:0042063,gliogenesis,M110,2,0
1,0,1,-5.3,0,-6.7,WP5174,Ulcerative colitis signaling,M101,2,0
1,1,0,-5.6,-3.3,0,M122,PID IL2 1PATHWAY,M110,2,0
1,1,0,-2.8,-2,0,R-HSA-525793,Myogenesis,M110,2,0
1,0,1,-4.4,0,-2.9,M36,PID IL27 PATHWAY,M101,2,0
1,1,0,-5.7,-3.9,0,GO:0002520,immune system development,M110,2,0
1,1,0,-2.6,-2.3,0,R-HSA-9725371,Nuclear events stimulated by ALK signaling in cancer,M110,2,0
1,1,0,-2.4,-2.1,0,GO:0060070,canonical Wnt signaling pathway,M110,2,0
1,1,0,-5.7,-4.6,0,GO:0060627,regulation of vesicle-mediated transport,M110,2,0
1,1,0,-5.4,-4.7,0,R-HSA-9664422,FCGR3A-mediated phagocytosis,M110,2,0
1,0,1,-6,0,-4.5,hsa05321,Inflammatory bowel disease,M101,2,0
1,1,0,-4.7,-3.7,0,GO:0042093,T-helper cell differentiation,M110,2,0
1,1,0,-2.2,-2.7,0,R-HSA-8878171,Transcriptional regulation by RUNX1,M110,2,0
1,1,0,-4.7,-3,0,GO:0032653,regulation of interleukin-10 production,M110,2,0
1,1,0,-2.9,-5.7,0,R-HSA-9664323,FCGR3A-mediated IL10 synthesis,M110,2,0
1,1,0,-4.5,-3.6,0,GO:0002287,alpha-beta T cell activation involved in immune response,M110,2,0
1,0,1,-2,0,-2.1,hsa05030,Cocaine addiction,M101,2,0
1,1,0,-3.6,-2.8,0,GO:0050864,regulation of B cell activation,M110,2,0
1,1,0,-2.8,-2.9,0,GO:0048844,artery morphogenesis,M110,2,0
1,1,0,-6,-2.3,0,WP2435,Quercetin and Nf kB AP 1 induced apoptosis,M110,2,0
1,1,0,-5.1,-3,0,R-HSA-6798695,Neutrophil degranulation,M110,2,0
1,1,0,-4.6,-2.4,0,WP4329,miRNA role in immune response in sepsis,M110,2,0
1,1,0,-4.2,-4.1,0,WP585,Interferon type I signaling pathways,M110,2,0
1,1,0,-5.4,-3.5,0,R-HSA-877300,Interferon gamma signaling,M110,2,0
1,1,0,-4.3,-3.1,0,GO:0007517,muscle organ development,M110,2,0
1,0,1,-3.6,0,-2.7,WP5144,NRP1 triggered signaling pathways in pancreatic cancer,M101,2,0
1,1,0,-2.8,-3.3,0,GO:0030100,regulation of endocytosis,M110,2,0
0,1,1,0,-2.3,-2.2,hsa04012,ErbB signaling pathway,M011,2,0
1,0,1,-3,0,-2.2,GO:0042742,defense response to bacterium,M101,2,0
1,1,0,-3.4,-2.3,0,GO:0045604,regulation of epidermal cell differentiation,M110,2,0
1,0,1,-5.8,0,-2.6,GO:0071219,cellular response to molecule of bacterial origin,M101,2,0
1,1,0,-3.3,-3.8,0,GO:0002718,regulation of cytokine production involved in immune response,M110,2,0
1,1,0,-5.4,-2.8,0,GO:0032680,regulation of tumor necrosis factor production,M110,2,0
1,1,0,-2,-2.2,0,R-HSA-354192,Integrin signaling,M110,2,0
1,1,0,-5.5,-4.9,0,R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,M110,2,0
1,1,0,-2.3,-2.3,0,GO:0060021,roof of mouth development,M110,2,0
1,1,0,-5.2,-2.2,0,WP4659,Gastrin signaling pathway,M110,2,0
1,1,0,-6.2,-3.8,0,GO:0046632,alpha-beta T cell differentiation,M110,2,0
1,1,0,-2.3,-2.6,0,GO:0060603,mammary gland duct morphogenesis,M110,2,0
1,1,0,-3.5,-3.1,0,GO:0050853,B cell receptor signaling pathway,M110,2,0
1,1,0,-2.3,-2.3,0,hsa05226,Gastric cancer,M110,2,0
0,1,0,0,-2.4,0,GO:0018212,peptidyl-tyrosine modification,M010,1,0
0,1,0,0,-2.5,0,GO:0032330,regulation of chondrocyte differentiation,M010,1,0
1,0,0,-2.3,0,0,GO:0097398,cellular response to interleukin-17,M100,1,0
1,0,0,-2.8,0,0,GO:0045589,regulation of regulatory T cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0045185,maintenance of protein location,M100,1,0
1,0,0,-3.8,0,0,GO:0033500,carbohydrate homeostasis,M100,1,0
1,0,0,-2,0,0,GO:0062207,regulation of pattern recognition receptor signaling pathway,M100,1,0
1,0,0,-3.3,0,0,GO:0050679,positive regulation of epithelial cell proliferation,M100,1,0
0,1,0,0,-2.8,0,GO:0046835,carbohydrate phosphorylation,M010,1,0
0,0,1,0,0,-2.4,GO:0097696,receptor signaling pathway via STAT,M001,1,0
1,0,0,-2,0,0,GO:0002532,production of molecular mediator involved in inflammatory response,M100,1,0
0,1,0,0,-3.4,0,hsa04973,Carbohydrate digestion and absorption,M010,1,0
1,0,0,-2.3,0,0,WP4868,Type I interferon induction and signaling during SARS CoV 2 infection,M100,1,0
1,0,0,-5.5,0,0,GO:0060541,respiratory system development,M100,1,0
0,1,0,0,-2.3,0,GO:0060099,"regulation of phagocytosis, engulfment",M010,1,0
0,1,0,0,-2.8,0,GO:1905007,positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation,M010,1,0
1,0,0,-2,0,0,GO:0002428,antigen processing and presentation of peptide antigen via MHC class Ib,M100,1,0
1,0,0,-3.4,0,0,M231,PID KIT PATHWAY,M100,1,0
1,0,0,-3.4,0,0,WP2895,Differentiation of white and brown adipocyte,M100,1,0
1,0,0,-3.6,0,0,GO:0001570,vasculogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0001657,ureteric bud development,M100,1,0
1,0,0,-2.1,0,0,WP3915,Angiopoietin like protein 8 regulatory pathway,M100,1,0
1,0,0,-2,0,0,WP2583,T cell receptor and co stimulatory signaling,M100,1,0
1,0,0,-2.5,0,0,WP410,Exercise induced circadian regulation,M100,1,0
1,0,0,-4.8,0,0,GO:0120161,regulation of cold-induced thermogenesis,M100,1,0
1,0,0,-4.8,0,0,GO:0034612,response to tumor necrosis factor,M100,1,0
1,0,0,-2.6,0,0,M233,PID EPO PATHWAY,M100,1,0
1,0,0,-5.3,0,0,GO:2000736,regulation of stem cell differentiation,M100,1,0
1,0,0,-2,0,0,GO:0048385,regulation of retinoic acid receptor signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0021988,olfactory lobe development,M100,1,0
1,0,0,-2.3,0,0,GO:0048839,inner ear development,M100,1,0
1,0,0,-2.2,0,0,GO:0014706,striated muscle tissue development,M100,1,0
1,0,0,-2.1,0,0,GO:0043302,positive regulation of leukocyte degranulation,M100,1,0
1,0,0,-4.4,0,0,R-HSA-975155,MyD88 dependent cascade initiated on endosome,M100,1,0
1,0,0,-2.8,0,0,GO:0006511,ubiquitin-dependent protein catabolic process,M100,1,0
1,0,0,-3.3,0,0,GO:1904893,negative regulation of receptor signaling pathway via STAT,M100,1,0
1,0,0,-2.6,0,0,M92,PID ANGIOPOIETIN RECEPTOR PATHWAY,M100,1,0
1,0,0,-3.1,0,0,WP4136,Fibrin complement receptor 3 signaling pathway,M100,1,0
1,0,0,-4.2,0,0,GO:0050767,regulation of neurogenesis,M100,1,0
1,0,0,-2.7,0,0,R-HSA-1839117,Signaling by cytosolic FGFR1 fusion mutants,M100,1,0
1,0,0,-6,0,0,GO:0032496,response to lipopolysaccharide,M100,1,0
1,0,0,-2.5,0,0,GO:0048589,developmental growth,M100,1,0
1,0,0,-2.9,0,0,hsa05217,Basal cell carcinoma,M100,1,0
1,0,0,-2.3,0,0,GO:0055123,digestive system development,M100,1,0
1,0,0,-3.1,0,0,GO:0071499,cellular response to laminar fluid shear stress,M100,1,0
0,0,1,0,0,-3.1,R-HSA-9013420,RHOU GTPase cycle,M001,1,0
1,0,0,-6.3,0,0,GO:0061138,morphogenesis of a branching epithelium,M100,1,0
1,0,0,-2.4,0,0,GO:0090596,sensory organ morphogenesis,M100,1,0
1,0,0,-2,0,0,WP3298,Melatonin metabolism and effects,M100,1,0
1,0,0,-4,0,0,M196,PID IL23 PATHWAY,M100,1,0
1,0,0,-2.7,0,0,GO:0051962,positive regulation of nervous system development,M100,1,0
0,1,0,0,-2.8,0,GO:0070669,response to interleukin-2,M010,1,0
1,0,0,-3.6,0,0,GO:1902692,regulation of neuroblast proliferation,M100,1,0
0,1,0,0,-3.4,0,R-HSA-164944,Nef and signal transduction,M010,1,0
0,1,0,0,-3.6,0,GO:0045061,thymic T cell selection,M010,1,0
1,0,0,-3.7,0,0,GO:1902075,cellular response to salt,M100,1,0
1,0,0,-5.5,0,0,GO:0007405,neuroblast proliferation,M100,1,0
1,0,0,-2,0,0,GO:0060509,type I pneumocyte differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0010575,positive regulation of vascular endothelial growth factor production,M100,1,0
1,0,0,-3.2,0,0,hsa05211,Renal cell carcinoma,M100,1,0
1,0,0,-2,0,0,WP3849,MAPK and NFkB signaling pathways inhibited by Yersinia YopJ,M100,1,0
0,1,0,0,-3.1,0,GO:0002313,mature B cell differentiation involved in immune response,M010,1,0
1,0,0,-6,0,0,GO:0031341,regulation of cell killing,M100,1,0
1,0,0,-2.6,0,0,WP3584,MECP2 and associated Rett syndrome,M100,1,0
1,0,0,-3.4,0,0,R-HSA-400206,Regulation of lipid metabolism by PPARalpha,M100,1,0
1,0,0,-2.4,0,0,GO:0002708,positive regulation of lymphocyte mediated immunity,M100,1,0
1,0,0,-6.2,0,0,GO:0050672,negative regulation of lymphocyte proliferation,M100,1,0
0,1,0,0,-2.4,0,R-HSA-983231,Factors involved in megakaryocyte development and platelet production,M010,1,0
1,0,0,-2.9,0,0,hsa05216,Thyroid cancer,M100,1,0
1,0,0,-2.5,0,0,R-HSA-4420097,VEGFA-VEGFR2 Pathway,M100,1,0
1,0,0,-2.9,0,0,GO:0052548,regulation of endopeptidase activity,M100,1,0
1,0,0,-3.3,0,0,GO:0043122,regulation of canonical NF-kappaB signal transduction,M100,1,0
1,0,0,-2.6,0,0,WP170,Nuclear receptors,M100,1,0
1,0,0,-3,0,0,R-HSA-975871,MyD88 cascade initiated on plasma membrane,M100,1,0
0,0,1,0,0,-2,GO:0018193,peptidyl-amino acid modification,M001,1,0
1,0,0,-4.8,0,0,GO:0071773,cellular response to BMP stimulus,M100,1,0
0,0,1,0,0,-3.8,GO:0030219,megakaryocyte differentiation,M001,1,0
1,0,0,-2.9,0,0,GO:0032689,negative regulation of type II interferon production,M100,1,0
0,1,0,0,-2.2,0,GO:0002431,Fc receptor mediated stimulatory signaling pathway,M010,1,0
1,0,0,-2.3,0,0,R-HSA-5683057,MAPK family signaling cascades,M100,1,0
1,0,0,-2.7,0,0,R-HSA-1236977,Endosomal/Vacuolar pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0010743,regulation of macrophage derived foam cell differentiation,M100,1,0
1,0,0,-8.1,0,0,GO:0001911,negative regulation of leukocyte mediated cytotoxicity,M100,1,0
1,0,0,-3.3,0,0,GO:0002295,T-helper cell lineage commitment,M100,1,0
1,0,0,-3.4,0,0,GO:0032755,positive regulation of interleukin-6 production,M100,1,0
1,0,0,-4.4,0,0,R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,M100,1,0
1,0,0,-3,0,0,WP399,Wnt signaling pathway and pluripotency,M100,1,0
1,0,0,-3,0,0,GO:0051052,regulation of DNA metabolic process,M100,1,0
0,1,0,0,-2.2,0,GO:0001958,endochondral ossification,M010,1,0
1,0,0,-2.1,0,0,WP4673,Male infertility,M100,1,0
0,1,0,0,-2.1,0,GO:0045670,regulation of osteoclast differentiation,M010,1,0
1,0,0,-4.3,0,0,GO:0120162,positive regulation of cold-induced thermogenesis,M100,1,0
1,0,0,-3.4,0,0,hsa05165,Human papillomavirus infection,M100,1,0
1,0,0,-4,0,0,GO:1904018,positive regulation of vasculature development,M100,1,0
0,1,0,0,-4.2,0,GO:0050766,positive regulation of phagocytosis,M010,1,0
1,0,0,-2.5,0,0,GO:0048565,digestive tract development,M100,1,0
0,1,0,0,-2.3,0,GO:1905153,regulation of membrane invagination,M010,1,0
1,0,0,-2.2,0,0,GO:0051897,positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M100,1,0
0,1,0,0,-3.4,0,GO:0046643,regulation of gamma-delta T cell activation,M010,1,0
1,0,0,-2.9,0,0,hsa04912,GnRH signaling pathway,M100,1,0
1,0,0,-2.6,0,0,hsa04623,Cytosolic DNA-sensing pathway,M100,1,0
0,1,0,0,-2.6,0,GO:0043299,leukocyte degranulation,M010,1,0
1,0,0,-2.9,0,0,GO:0009595,detection of biotic stimulus,M100,1,0
1,0,0,-2.3,0,0,GO:0062197,cellular response to chemical stress,M100,1,0
1,0,0,-2,0,0,GO:0045954,positive regulation of natural killer cell mediated cytotoxicity,M100,1,0
0,1,0,0,-2,0,GO:0048799,animal organ maturation,M010,1,0
1,0,0,-3,0,0,R-HSA-1989781,PPARA activates gene expression,M100,1,0
0,1,0,0,-2.6,0,GO:0050732,negative regulation of peptidyl-tyrosine phosphorylation,M010,1,0
1,0,0,-2.4,0,0,WP474,Endochondral ossification,M100,1,0
1,0,0,-4.5,0,0,GO:0001944,vasculature development,M100,1,0
0,0,1,0,0,-2.4,GO:0045806,negative regulation of endocytosis,M001,1,0
1,0,0,-2.1,0,0,GO:1990869,cellular response to chemokine,M100,1,0
1,0,0,-2.4,0,0,WP4269,Ethanol metabolism production of ROS by CYP2E1,M100,1,0
1,0,0,-2.1,0,0,GO:0045667,regulation of osteoblast differentiation,M100,1,0
1,0,0,-2.4,0,0,R-HSA-210990,PECAM1 interactions,M100,1,0
1,0,0,-2.4,0,0,WP3926,ApoE and miR 146 in inflammation and atherosclerosis,M100,1,0
1,0,0,-4,0,0,M105,PID TELOMERASE PATHWAY,M100,1,0
1,0,0,-2.3,0,0,GO:2000178,negative regulation of neural precursor cell proliferation,M100,1,0
1,0,0,-3.1,0,0,WP5092,Interactions of natural killer cells in pancreatic cancer,M100,1,0
1,0,0,-2.3,0,0,GO:1990791,dorsal root ganglion development,M100,1,0
1,0,0,-3,0,0,R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,M100,1,0
1,0,0,-2.3,0,0,GO:0001704,formation of primary germ layer,M100,1,0
1,0,0,-3.1,0,0,R-HSA-1839124,FGFR1 mutant receptor activation,M100,1,0
1,0,0,-3.4,0,0,GO:0002705,positive regulation of leukocyte mediated immunity,M100,1,0
1,0,0,-2.2,0,0,GO:0062013,positive regulation of small molecule metabolic process,M100,1,0
1,0,0,-2.4,0,0,GO:0042770,signal transduction in response to DNA damage,M100,1,0
1,0,0,-2.3,0,0,GO:0071317,cellular response to isoquinoline alkaloid,M100,1,0
1,0,0,-2.3,0,0,GO:0045626,negative regulation of T-helper 1 cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:2000516,"positive regulation of CD4-positive, alpha-beta T cell activation",M100,1,0
1,0,0,-2,0,0,R-HSA-190373,FGFR1c ligand binding and activation,M100,1,0
1,0,0,-2,0,0,M1718,SIG IL4RECEPTOR IN B LYPHOCYTES,M100,1,0
1,0,0,-2.7,0,0,M180,PID HIF1A PATHWAY,M100,1,0
1,0,0,-2,0,0,GO:0045830,positive regulation of isotype switching,M100,1,0
1,0,0,-2.6,0,0,GO:0002825,regulation of T-helper 1 type immune response,M100,1,0
1,0,0,-2.4,0,0,GO:0002576,platelet degranulation,M100,1,0
1,0,0,-2.8,0,0,GO:0048762,mesenchymal cell differentiation,M100,1,0
1,0,0,-4.2,0,0,R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,M100,1,0
1,0,0,-2.6,0,0,M161,PID IFNG PATHWAY,M100,1,0
1,0,0,-2.4,0,0,WP5066,FOXA2 pathway,M100,1,0
0,0,1,0,0,-2.1,GO:0006259,DNA metabolic process,M001,1,0
1,0,0,-2.7,0,0,WP4172,PI3K Akt signaling pathway,M100,1,0
1,0,0,-4.5,0,0,GO:0010594,regulation of endothelial cell migration,M100,1,0
1,0,0,-2.1,0,0,GO:0061371,determination of heart left/right asymmetry,M100,1,0
1,0,0,-3.7,0,0,hsa04926,Relaxin signaling pathway,M100,1,0
1,0,0,-2.3,0,0,M264,PID TOLL ENDOGENOUS PATHWAY,M100,1,0
0,1,0,0,-4,0,GO:0045064,T-helper 2 cell differentiation,M010,1,0
1,0,0,-3.8,0,0,R-HSA-1059683,Interleukin-6 signaling,M100,1,0
1,0,0,-2,0,0,GO:0045428,regulation of nitric oxide biosynthetic process,M100,1,0
1,0,0,-3.4,0,0,GO:0002821,positive regulation of adaptive immune response,M100,1,0
0,1,0,0,-2.8,0,hsa04670,Leukocyte transendothelial migration,M010,1,0
1,0,0,-3.9,0,0,GO:0032757,positive regulation of interleukin-8 production,M100,1,0
1,0,0,-3.4,0,0,GO:0001914,regulation of T cell mediated cytotoxicity,M100,1,0
1,0,0,-5.4,0,0,R-HSA-2990846,SUMOylation,M100,1,0
1,0,0,-4.6,0,0,GO:0140888,interferon-mediated signaling pathway,M100,1,0
1,0,0,-3.1,0,0,GO:0035589,G protein-coupled purinergic nucleotide receptor signaling pathway,M100,1,0
1,0,0,-3.1,0,0,GO:0022030,telencephalon glial cell migration,M100,1,0
1,0,0,-2.3,0,0,R-HSA-1679131,Trafficking and processing of endosomal TLR,M100,1,0
1,0,0,-2.4,0,0,GO:0002476,antigen processing and presentation of endogenous peptide antigen via MHC class Ib,M100,1,0
1,0,0,-3.1,0,0,GO:0003007,heart morphogenesis,M100,1,0
1,0,0,-3.8,0,0,GO:0006974,DNA damage response,M100,1,0
1,0,0,-5.7,0,0,GO:0048705,skeletal system morphogenesis,M100,1,0
1,0,0,-3.1,0,0,GO:0006984,ER-nucleus signaling pathway,M100,1,0
1,0,0,-3.1,0,0,GO:0030163,protein catabolic process,M100,1,0
1,0,0,-3.8,0,0,GO:0001890,placenta development,M100,1,0
0,1,0,0,-2.5,0,GO:2000679,positive regulation of transcription regulatory region DNA binding,M010,1,0
1,0,0,-4.4,0,0,hsa04657,IL-17 signaling pathway,M100,1,0
1,0,0,-2.1,0,0,WP4396,Nonalcoholic fatty liver disease,M100,1,0
1,0,0,-2.9,0,0,GO:0007264,small GTPase mediated signal transduction,M100,1,0
1,0,0,-4.2,0,0,GO:0048514,blood vessel morphogenesis,M100,1,0
1,0,0,-2,0,0,GO:0097306,cellular response to alcohol,M100,1,0
0,1,0,0,-3.1,0,GO:0007159,leukocyte cell-cell adhesion,M010,1,0
1,0,0,-2.7,0,0,hsa05208,Chemical carcinogenesis - reactive oxygen species,M100,1,0
1,0,0,-2.1,0,0,GO:0016525,negative regulation of angiogenesis,M100,1,0
1,0,0,-2.7,0,0,hsa04310,Wnt signaling pathway,M100,1,0
1,0,0,-2.6,0,0,GO:0002685,regulation of leukocyte migration,M100,1,0
1,0,0,-2.2,0,0,GO:0009755,hormone-mediated signaling pathway,M100,1,0
1,0,0,-2.9,0,0,GO:1990823,response to leukemia inhibitory factor,M100,1,0
1,0,0,-4.2,0,0,GO:0071496,cellular response to external stimulus,M100,1,0
0,1,0,0,-2,0,GO:0031641,regulation of myelination,M010,1,0
1,0,0,-2.1,0,0,GO:0032647,regulation of interferon-alpha production,M100,1,0
1,0,0,-2.3,0,0,GO:2000741,positive regulation of mesenchymal stem cell differentiation,M100,1,0
0,1,0,0,-2.2,0,hsa00051,Fructose and mannose metabolism,M010,1,0
1,0,0,-3.8,0,0,WP4746,Thyroid hormones production and peripheral downstream signaling effects,M100,1,0
0,1,0,0,-3,0,GO:0050854,regulation of antigen receptor-mediated signaling pathway,M010,1,0
0,1,0,0,-2.2,0,R-HSA-8949275,RUNX3 Regulates Immune Response and Cell Migration,M010,1,0
1,0,0,-2.5,0,0,M145,PID P53 DOWNSTREAM PATHWAY,M100,1,0
1,0,0,-3.2,0,0,GO:0001959,regulation of cytokine-mediated signaling pathway,M100,1,0
1,0,0,-3.8,0,0,GO:0001936,regulation of endothelial cell proliferation,M100,1,0
0,1,0,0,-4.9,0,hsa04611,Platelet activation,M010,1,0
1,0,0,-2.3,0,0,GO:0060340,positive regulation of type I interferon-mediated signaling pathway,M100,1,0
1,0,0,-2.7,0,0,R-HSA-8941326,RUNX2 regulates bone development,M100,1,0
0,1,0,0,-2.4,0,GO:0045059,positive thymic T cell selection,M010,1,0
1,0,0,-2.3,0,0,CORUM:826,PAR-3-VE-cadherin-beta-catenin complex,M100,1,0
1,0,0,-2.7,0,0,R-HSA-8878166,Transcriptional regulation by RUNX2,M100,1,0
1,0,0,-2.5,0,0,GO:0050921,positive regulation of chemotaxis,M100,1,0
1,0,0,-4.8,0,0,GO:0071772,response to BMP,M100,1,0
1,0,0,-2.7,0,0,GO:0032481,positive regulation of type I interferon production,M100,1,0
0,1,0,0,-2,0,GO:0061035,regulation of cartilage development,M010,1,0
1,0,0,-5.3,0,0,GO:1901342,regulation of vasculature development,M100,1,0
1,0,0,-2.1,0,0,R-HSA-5654726,Negative regulation of FGFR1 signaling,M100,1,0
0,1,0,0,-2.2,0,WP4565,Neural crest cell migration in cancer,M010,1,0
0,1,0,0,-2.1,0,hsa04371,Apelin signaling pathway,M010,1,0
1,0,0,-2.8,0,0,GO:0010038,response to metal ion,M100,1,0
0,1,0,0,-3.4,0,CORUM:2909,PLC-gamma-2-Syk-LAT-FcR-gamma complex,M010,1,0
1,0,0,-2.4,0,0,hsa04151,PI3K-Akt signaling pathway,M100,1,0
1,0,0,-3.1,0,0,GO:0043010,camera-type eye development,M100,1,0
0,0,1,0,0,-2.5,GO:0104004,cellular response to environmental stimulus,M001,1,0
1,0,0,-2.1,0,0,hsa04728,Dopaminergic synapse,M100,1,0
1,0,0,-4.2,0,0,GO:0032703,negative regulation of interleukin-2 production,M100,1,0
1,0,0,-4,0,0,WP3678,Amplification and expansion of oncogenic pathways as metastatic traits,M100,1,0
1,0,0,-2.3,0,0,R-HSA-381771,"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",M100,1,0
0,1,0,0,-3.4,0,GO:0019042,viral latency,M010,1,0
1,0,0,-2.1,0,0,WP5358,JAK STAT signaling in the regulation of Beta cells,M100,1,0
1,0,0,-5.2,0,0,WP1544,MicroRNAs in cardiomyocyte hypertrophy,M100,1,0
0,0,1,0,0,-2.3,GO:1903055,positive regulation of extracellular matrix organization,M001,1,0
1,0,0,-3.5,0,0,GO:0042594,response to starvation,M100,1,0
0,1,0,0,-2.2,0,WP4564,Neural crest cell migration during development,M010,1,0
0,1,0,0,-2.8,0,GO:0002885,positive regulation of hypersensitivity,M010,1,0
1,0,0,-2.1,0,0,GO:1990868,response to chemokine,M100,1,0
1,0,0,-2,0,0,R-HSA-381183,ATF6 (ATF6-alpha) activates chaperone genes,M100,1,0
1,0,0,-2,0,0,GO:0045628,regulation of T-helper 2 cell differentiation,M100,1,0
1,0,0,-9.8,0,0,GO:0008285,negative regulation of cell population proliferation,M100,1,0
1,0,0,-2.5,0,0,GO:0001503,ossification,M100,1,0
1,0,0,-2.6,0,0,GO:0060795,cell fate commitment involved in formation of primary germ layer,M100,1,0
1,0,0,-2.3,0,0,R-HSA-389513,CTLA4 inhibitory signaling,M100,1,0
0,1,0,0,-2.8,0,GO:0001794,type IIa hypersensitivity,M010,1,0
1,0,0,-3.4,0,0,GO:0043280,positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,M100,1,0
1,0,0,-3.5,0,0,GO:2001056,positive regulation of cysteine-type endopeptidase activity,M100,1,0
0,1,0,0,-2.2,0,GO:0060416,response to growth hormone,M010,1,0
1,0,0,-2.6,0,0,GO:0072538,T-helper 17 type immune response,M100,1,0
1,0,0,-2.4,0,0,R-HSA-1368108,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",M100,1,0
1,0,0,-2.3,0,0,R-HSA-5654736,Signaling by FGFR1,M100,1,0
1,0,0,-3.2,0,0,GO:0003143,embryonic heart tube morphogenesis,M100,1,0
1,0,0,-3,0,0,hsa04934,Cushing syndrome,M100,1,0
0,1,0,0,-2.2,0,GO:0009620,response to fungus,M010,1,0
1,0,0,-3.7,0,0,WP710,DNA damage response only ATM dependent,M100,1,0
1,0,0,-3.1,0,0,GO:0071354,cellular response to interleukin-6,M100,1,0
0,1,0,0,-2.2,0,GO:0007398,ectoderm development,M010,1,0
1,0,0,-3.1,0,0,GO:0010742,macrophage derived foam cell differentiation,M100,1,0
1,0,0,-2.6,0,0,GO:1901983,regulation of protein acetylation,M100,1,0
1,0,0,-2.6,0,0,GO:0071357,cellular response to type I interferon,M100,1,0
1,0,0,-3.8,0,0,GO:2000739,regulation of mesenchymal stem cell differentiation,M100,1,0
1,0,0,-2.1,0,0,hsa04622,RIG-I-like receptor signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0042692,muscle cell differentiation,M100,1,0
1,0,0,-2.8,0,0,GO:0043281,regulation of cysteine-type endopeptidase activity involved in apoptotic process,M100,1,0
1,0,0,-2.9,0,0,GO:0045191,regulation of isotype switching,M100,1,0
1,0,0,-2.3,0,0,R-HSA-112411,MAPK1 (ERK2) activation,M100,1,0
1,0,0,-5,0,0,GO:0007178,transmembrane receptor protein serine/threonine kinase signaling pathway,M100,1,0
1,0,0,-4.1,0,0,GO:1902532,negative regulation of intracellular signal transduction,M100,1,0
1,0,0,-5.7,0,0,GO:0032649,regulation of type II interferon production,M100,1,0
1,0,0,-2.8,0,0,GO:0071248,cellular response to metal ion,M100,1,0
0,0,1,0,0,-2,GO:1904035,regulation of epithelial cell apoptotic process,M001,1,0
1,0,0,-2.1,0,0,WP4756,Renin angiotensin aldosterone system RAAS,M100,1,0
1,0,0,-2.2,0,0,GO:0060612,adipose tissue development,M100,1,0
1,0,0,-2,0,0,R-HSA-6783783,Interleukin-10 signaling,M100,1,0
1,0,0,-2.1,0,0,GO:0001569,branching involved in blood vessel morphogenesis,M100,1,0
1,0,0,-2,0,0,GO:0008064,regulation of actin polymerization or depolymerization,M100,1,0
1,0,0,-2.7,0,0,GO:0007369,gastrulation,M100,1,0
1,0,0,-3.4,0,0,GO:0043368,positive T cell selection,M100,1,0
1,0,0,-2.9,0,0,R-HSA-4090294,SUMOylation of intracellular receptors,M100,1,0
1,0,0,-5.4,0,0,hsa05132,Salmonella infection,M100,1,0
1,0,0,-2.7,0,0,GO:0033151,V(D)J recombination,M100,1,0
1,0,0,-2.5,0,0,GO:0040007,growth,M100,1,0
1,0,0,-2.3,0,0,GO:0001829,trophectodermal cell differentiation,M100,1,0
1,0,0,-4,0,0,GO:0042475,odontogenesis of dentin-containing tooth,M100,1,0
1,0,0,-2.3,0,0,CORUM:1816,JUN-TCF4-CTNNB1 complex,M100,1,0
1,0,0,-2,0,0,R-HSA-1606322,ZBP1(DAI) mediated induction of type I IFNs,M100,1,0
1,0,0,-2.4,0,0,M236,PID DELTA NP63 PATHWAY,M100,1,0
1,0,0,-3.1,0,0,GO:0002562,somatic diversification of immune receptors via germline recombination within a single locus,M100,1,0
1,0,0,-4.1,0,0,GO:0030856,regulation of epithelial cell differentiation,M100,1,0
1,0,0,-2.6,0,0,WP5381,Smith Magenis and Potocki Lupski syndrome copy number variation,M100,1,0
0,1,0,0,-2.3,0,R-HSA-9013404,RAC2 GTPase cycle,M010,1,0
1,0,0,-6,0,0,GO:0001910,regulation of leukocyte mediated cytotoxicity,M100,1,0
1,0,0,-2.3,0,0,GO:0002774,Fc receptor mediated inhibitory signaling pathway,M100,1,0
1,0,0,-2.3,0,0,R-HSA-9022699,MECP2 regulates neuronal receptors and channels,M100,1,0
1,0,0,-2.1,0,0,GO:0060216,definitive hemopoiesis,M100,1,0
1,0,0,-2.9,0,0,GO:0032642,regulation of chemokine production,M100,1,0
1,0,0,-2.9,0,0,GO:0007169,transmembrane receptor protein tyrosine kinase signaling pathway,M100,1,0
0,0,1,0,0,-3.6,R-HSA-74158,RNA Polymerase III Transcription,M001,1,0
1,0,0,-4.3,0,0,GO:0048754,branching morphogenesis of an epithelial tube,M100,1,0
1,0,0,-2,0,0,GO:0032570,response to progesterone,M100,1,0
1,0,0,-2.2,0,0,R-HSA-5357801,Programmed Cell Death,M100,1,0
1,0,0,-3.9,0,0,GO:0046683,response to organophosphorus,M100,1,0
0,1,0,0,-2.4,0,GO:0002864,regulation of acute inflammatory response to antigenic stimulus,M010,1,0
1,0,0,-2,0,0,R-HSA-5603041,IRAK4 deficiency (TLR2/4),M100,1,0
1,0,0,-2.3,0,0,R-HSA-9683701,Translation of Structural Proteins,M100,1,0
1,0,0,-3.3,0,0,GO:0019827,stem cell population maintenance,M100,1,0
1,0,0,-3.4,0,0,GO:0002360,T cell lineage commitment,M100,1,0
1,0,0,-3.6,0,0,GO:0048706,embryonic skeletal system development,M100,1,0
1,0,0,-10,0,0,GO:0071396,cellular response to lipid,M100,1,0
1,0,0,-3.3,0,0,R-HSA-9670439,"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",M100,1,0
1,0,0,-3.2,0,0,GO:0010883,regulation of lipid storage,M100,1,0
1,0,0,-2.5,0,0,M286,PID TGFBR PATHWAY,M100,1,0
1,0,0,-3.9,0,0,GO:0017157,regulation of exocytosis,M100,1,0
0,1,0,0,-2.1,0,GO:0003208,cardiac ventricle morphogenesis,M010,1,0
1,0,0,-3.3,0,0,GO:0040013,negative regulation of locomotion,M100,1,0
1,0,0,-4.2,0,0,GO:0010595,positive regulation of endothelial cell migration,M100,1,0
1,0,0,-2.3,0,0,GO:0042532,negative regulation of tyrosine phosphorylation of STAT protein,M100,1,0
1,0,0,-2.4,0,0,GO:0090184,positive regulation of kidney development,M100,1,0
0,0,1,0,0,-2.4,GO:0007259,receptor signaling pathway via JAK-STAT,M001,1,0
1,0,0,-2.3,0,0,GO:0048293,regulation of isotype switching to IgE isotypes,M100,1,0
1,0,0,-4.7,0,0,R-HSA-400253,Circadian Clock,M100,1,0
0,1,0,0,-2,0,GO:0009988,cell-cell recognition,M010,1,0
1,0,0,-2.1,0,0,WP4838,Regucalcin in proximal tubule epithelial kidney cells,M100,1,0
1,0,0,-2.3,0,0,R-HSA-389359,CD28 dependent Vav1 pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0009247,glycolipid biosynthetic process,M100,1,0
1,0,0,-2.7,0,0,CORUM:5193,"TNF-alpha/NF-kappa B signaling complex (CHUK, KPNA3, NFKB2, NFKBIB, REL, IKBKG,  NFKB1, NFKBIE, RELB,  NFKBIA, RELA, TNIP2)",M100,1,0
1,0,0,-5.2,0,0,hsa05145,Toxoplasmosis,M100,1,0
1,0,0,-2.3,0,0,GO:0015914,phospholipid transport,M100,1,0
1,0,0,-2.9,0,0,WP2839,Hair follicle development organogenesis part 2 of 3,M100,1,0
1,0,0,-5.7,0,0,GO:0030162,regulation of proteolysis,M100,1,0
1,0,0,-5.3,0,0,M206,PID PDGFRA PATHWAY,M100,1,0
1,0,0,-3.5,0,0,GO:0048704,embryonic skeletal system morphogenesis,M100,1,0
0,1,0,0,-3.6,0,GO:0050852,T cell receptor signaling pathway,M010,1,0
0,1,0,0,-4,0,GO:0043392,negative regulation of DNA binding,M010,1,0
1,0,0,-4,0,0,WP363,Wnt signaling pathway,M100,1,0
0,1,0,0,-2.4,0,GO:0046456,icosanoid biosynthetic process,M010,1,0
1,0,0,-3.8,0,0,GO:0098543,detection of other organism,M100,1,0
1,0,0,-2.9,0,0,hsa05020,Prion disease,M100,1,0
0,1,0,0,-2.2,0,R-HSA-9013423,RAC3 GTPase cycle,M010,1,0
1,0,0,-5.3,0,0,GO:0009991,response to extracellular stimulus,M100,1,0
1,0,0,-4.7,0,0,hsa04010,MAPK signaling pathway,M100,1,0
1,0,0,-2.1,0,0,hsa05330,Allograft rejection,M100,1,0
1,0,0,-2.2,0,0,hsa04916,Melanogenesis,M100,1,0
0,0,1,0,0,-2.1,R-HSA-450294,MAP kinase activation,M001,1,0
1,0,0,-2.7,0,0,WP1991,SRF and miRs in smooth muscle differentiation and proliferation,M100,1,0
1,0,0,-3.3,0,0,hsa05416,Viral myocarditis,M100,1,0
1,0,0,-2,0,0,R-HSA-452723,Transcriptional regulation of pluripotent stem cells,M100,1,0
1,0,0,-2.9,0,0,R-HSA-9671555,Signaling by PDGFR in disease,M100,1,0
1,0,0,-3.7,0,0,WP5348,11p11 2 copy number variation syndrome,M100,1,0
0,0,1,0,0,-2.8,GO:0097581,lamellipodium organization,M001,1,0
1,0,0,-3.4,0,0,GO:0032673,regulation of interleukin-4 production,M100,1,0
1,0,0,-2.3,0,0,WP5038,Mitochondrial immune response to SARS CoV 2,M100,1,0
0,1,0,0,-2.8,0,R-HSA-5621480,Dectin-2 family,M010,1,0
0,1,0,0,-2.3,0,GO:2000677,regulation of transcription regulatory region DNA binding,M010,1,0
1,0,0,-2.1,0,0,GO:0010633,negative regulation of epithelial cell migration,M100,1,0
0,1,0,0,-2.2,0,M190,PID TCR JNK PATHWAY,M010,1,0
1,0,0,-3.4,0,0,GO:0021885,forebrain cell migration,M100,1,0
1,0,0,-2.3,0,0,GO:0060966,regulation of gene silencing by regulatory ncRNA,M100,1,0
1,0,0,-2.6,0,0,R-HSA-982772,Growth hormone receptor signaling,M100,1,0
0,1,0,0,-2.2,0,hsa01522,Endocrine resistance,M010,1,0
1,0,0,-3.5,0,0,WP581,EPO receptor signaling,M100,1,0
0,1,0,0,-2.2,0,WP4784,Proteoglycan biosynthesis,M010,1,0
1,0,0,-3.4,0,0,GO:0051054,positive regulation of DNA metabolic process,M100,1,0
1,0,0,-4,0,0,GO:0071375,cellular response to peptide hormone stimulus,M100,1,0
0,1,0,0,-2,0,GO:0002377,immunoglobulin production,M010,1,0
1,0,0,-2.6,0,0,hsa05332,Graft-versus-host disease,M100,1,0
0,1,0,0,-3.3,0,GO:0007229,integrin-mediated signaling pathway,M010,1,0
1,0,0,-2.2,0,0,hsa05320,Autoimmune thyroid disease,M100,1,0
1,0,0,-2.4,0,0,GO:0097264,self proteolysis,M100,1,0
0,1,0,0,-2,0,WP5411,Phosphatidyl inositol phosphate pathway,M010,1,0
1,0,0,-5.8,0,0,GO:0030522,intracellular receptor signaling pathway,M100,1,0
1,0,0,-2.6,0,0,GO:0070328,triglyceride homeostasis,M100,1,0
1,0,0,-3.5,0,0,GO:0045598,regulation of fat cell differentiation,M100,1,0
1,0,0,-4.2,0,0,GO:0014074,response to purine-containing compound,M100,1,0
1,0,0,-2.3,0,0,GO:0010458,exit from mitosis,M100,1,0
0,1,0,0,-2.5,0,M50,PID PTP1B PATHWAY,M010,1,0
1,0,0,-2.3,0,0,GO:0019941,modification-dependent protein catabolic process,M100,1,0
0,1,0,0,-2.8,0,GO:0001788,antibody-dependent cellular cytotoxicity,M010,1,0
0,1,0,0,-3,0,GO:0002444,myeloid leukocyte mediated immunity,M010,1,0
1,0,0,-2.3,0,0,GO:1901741,positive regulation of myoblast fusion,M100,1,0
1,0,0,-2.4,0,0,WP4263,Pancreatic adenocarcinoma pathway,M100,1,0
1,0,0,-3.4,0,0,GO:0034204,lipid translocation,M100,1,0
1,0,0,-2.3,0,0,R-HSA-1461973,Defensins,M100,1,0
1,0,0,-4.8,0,0,WP2064,Neural crest differentiation,M100,1,0
1,0,0,-5.4,0,0,R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,M100,1,0
1,0,0,-2.9,0,0,WP5124,Alzheimer 39 s disease,M100,1,0
1,0,0,-3.3,0,0,GO:0001654,eye development,M100,1,0
0,0,1,0,0,-4,R-HSA-8951936,RUNX3 regulates p14-ARF,M001,1,0
0,0,1,0,0,-3,GO:0035855,megakaryocyte development,M001,1,0
0,0,1,0,0,-2.4,R-HSA-1912408,Pre-NOTCH Transcription and Translation,M001,1,0
1,0,0,-2.3,0,0,WP4482,Vitamin D in inflammatory diseases,M100,1,0
1,0,0,-2.1,0,0,M19,PID P73PATHWAY,M100,1,0
1,0,0,-3.9,0,0,R-HSA-9006925,Intracellular signaling by second messengers,M100,1,0
1,0,0,-2.3,0,0,GO:0060964,regulation of miRNA-mediated gene silencing,M100,1,0
1,0,0,-2.5,0,0,GO:0045664,regulation of neuron differentiation,M100,1,0
0,1,0,0,-3,0,GO:0043376,"regulation of CD8-positive, alpha-beta T cell differentiation",M010,1,0
1,0,0,-3.1,0,0,R-HSA-450341,Activation of the AP-1 family of transcription factors,M100,1,0
1,0,0,-2.8,0,0,WP5094,Orexin receptor pathway,M100,1,0
1,0,0,-2,0,0,GO:0021984,adenohypophysis development,M100,1,0
1,0,0,-3.9,0,0,GO:0021543,pallium development,M100,1,0
1,0,0,-2.3,0,0,GO:0051048,negative regulation of secretion,M100,1,0
1,0,0,-2.2,0,0,GO:0032732,positive regulation of interleukin-1 production,M100,1,0
1,0,0,-2.3,0,0,GO:0032714,negative regulation of interleukin-5 production,M100,1,0
1,0,0,-2.2,0,0,GO:0045814,"negative regulation of gene expression, epigenetic",M100,1,0
1,0,0,-2.4,0,0,GO:0032814,regulation of natural killer cell activation,M100,1,0
1,0,0,-3.3,0,0,GO:0030595,leukocyte chemotaxis,M100,1,0
1,0,0,-5.4,0,0,GO:0007507,heart development,M100,1,0
1,0,0,-2.1,0,0,GO:0045577,regulation of B cell differentiation,M100,1,0
0,1,0,0,-2.2,0,GO:0048752,semicircular canal morphogenesis,M010,1,0
0,1,0,0,-2.2,0,GO:0034135,regulation of toll-like receptor 2 signaling pathway,M010,1,0
1,0,0,-3.1,0,0,GO:0097530,granulocyte migration,M100,1,0
1,0,0,-4.6,0,0,WP2858,Ectoderm differentiation,M100,1,0
1,0,0,-2.4,0,0,hsa04710,Circadian rhythm,M100,1,0
1,0,0,-4.7,0,0,R-HSA-8943724,Regulation of PTEN gene transcription,M100,1,0
1,0,0,-2.4,0,0,GO:0072540,T-helper 17 cell lineage commitment,M100,1,0
0,1,0,0,-3.5,0,GO:0051282,regulation of sequestering of calcium ion,M010,1,0
1,0,0,-2.2,0,0,hsa04072,Phospholipase D signaling pathway,M100,1,0
1,0,0,-3.1,0,0,GO:0046426,negative regulation of receptor signaling pathway via JAK-STAT,M100,1,0
1,0,0,-2.9,0,0,R-HSA-3232118,SUMOylation of transcription factors,M100,1,0
1,0,0,-4.6,0,0,GO:0031667,response to nutrient levels,M100,1,0
1,0,0,-3.8,0,0,R-HSA-9758941,Gastrulation,M100,1,0
1,0,0,-3.2,0,0,GO:0010035,response to inorganic substance,M100,1,0
1,0,0,-3.7,0,0,R-HSA-9013407,RHOH GTPase cycle,M100,1,0
1,0,0,-2.6,0,0,M81,PID CDC42 PATHWAY,M100,1,0
1,0,0,-4.6,0,0,R-HSA-389356,CD28 co-stimulation,M100,1,0
1,0,0,-2.4,0,0,GO:0002484,antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0002664,regulation of T cell tolerance induction,M100,1,0
1,0,0,-3.1,0,0,GO:0070542,response to fatty acid,M100,1,0
1,0,0,-2,0,0,GO:0001649,osteoblast differentiation,M100,1,0
0,0,1,0,0,-2.9,GO:0030032,lamellipodium assembly,M001,1,0
1,0,0,-2.6,0,0,GO:0097190,apoptotic signaling pathway,M100,1,0
0,0,1,0,0,-2.5,GO:0071214,cellular response to abiotic stimulus,M001,1,0
1,0,0,-2.7,0,0,M44,PID HIF2PATHWAY,M100,1,0
1,0,0,-2.7,0,0,WP5216,Warburg effect modulated by deubiquitinating enzymes and their substrates,M100,1,0
1,0,0,-2.6,0,0,hsa05323,Rheumatoid arthritis,M100,1,0
1,0,0,-3.2,0,0,M229,PID P38 ALPHA BETA DOWNSTREAM PATHWAY,M100,1,0
1,0,0,-3.3,0,0,R-HSA-9669938,Signaling by KIT in disease,M100,1,0
1,0,0,-2.2,0,0,GO:0021987,cerebral cortex development,M100,1,0
0,1,0,0,-3.4,0,GO:0030888,regulation of B cell proliferation,M010,1,0
1,0,0,-2.1,0,0,GO:0048701,embryonic cranial skeleton morphogenesis,M100,1,0
1,0,0,-2.6,0,0,GO:0010574,regulation of vascular endothelial growth factor production,M100,1,0
0,1,0,0,-2.2,0,GO:0061081,positive regulation of myeloid leukocyte cytokine production involved in immune response,M010,1,0
1,0,0,-2.9,0,0,GO:2000269,regulation of fibroblast apoptotic process,M100,1,0
1,0,0,-4.1,0,0,WP4842,Mammalian disorder of sexual development,M100,1,0
1,0,0,-3,0,0,GO:0015850,organic hydroxy compound transport,M100,1,0
1,0,0,-2.1,0,0,GO:0071456,cellular response to hypoxia,M100,1,0
1,0,0,-3.1,0,0,R-HSA-5655302,Signaling by FGFR1 in disease,M100,1,0
1,0,0,-3,0,0,GO:0042472,inner ear morphogenesis,M100,1,0
1,0,0,-2.3,0,0,GO:0045920,negative regulation of exocytosis,M100,1,0
1,0,0,-4.8,0,0,GO:0060322,head development,M100,1,0
1,0,0,-2.4,0,0,M185,PID ALK1 PATHWAY,M100,1,0
0,1,0,0,-2.2,0,GO:0002438,acute inflammatory response to antigenic stimulus,M010,1,0
1,0,0,-2.7,0,0,GO:0002824,positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M100,1,0
1,0,0,-2.4,0,0,GO:0001656,metanephros development,M100,1,0
1,0,0,-3.1,0,0,GO:0098581,detection of external biotic stimulus,M100,1,0
1,0,0,-3.1,0,0,R-HSA-400508,"Incretin synthesis, secretion, and inactivation",M100,1,0
1,0,0,-2.3,0,0,GO:0070828,heterochromatin organization,M100,1,0
1,0,0,-4,0,0,GO:0050792,regulation of viral process,M100,1,0
1,0,0,-3.4,0,0,R-HSA-198725,Nuclear Events (kinase and transcription factor activation),M100,1,0
0,1,0,0,-2.9,0,GO:0002720,positive regulation of cytokine production involved in immune response,M010,1,0
1,0,0,-2.4,0,0,GO:0002826,negative regulation of T-helper 1 type immune response,M100,1,0
1,0,0,-2.6,0,0,WP5331,Autophagy in pancreatic ductal adenocarcinoma,M100,1,0
1,0,0,-2.6,0,0,GO:1990266,neutrophil migration,M100,1,0
1,0,0,-2.3,0,0,GO:0034599,cellular response to oxidative stress,M100,1,0
1,0,0,-3.8,0,0,GO:0060759,regulation of response to cytokine stimulus,M100,1,0
1,0,0,-2.7,0,0,GO:0002064,epithelial cell development,M100,1,0
1,0,0,-3.6,0,0,WP4844,Influence of laminopathies on Wnt signaling,M100,1,0
1,0,0,-2.6,0,0,GO:0030036,actin cytoskeleton organization,M100,1,0
1,0,0,-2.6,0,0,GO:2000737,negative regulation of stem cell differentiation,M100,1,0
1,0,0,-2.9,0,0,GO:0071675,regulation of mononuclear cell migration,M100,1,0
0,1,0,0,-3.4,0,GO:0001796,regulation of type IIa hypersensitivity,M010,1,0
1,0,0,-2.7,0,0,GO:0060976,coronary vasculature development,M100,1,0
1,0,0,-4,0,0,M226,PID VEGFR1 PATHWAY,M100,1,0
0,1,0,0,-2.2,0,GO:2000392,regulation of lamellipodium morphogenesis,M010,1,0
1,0,0,-2.3,0,0,GO:1900368,regulation of post-transcriptional gene silencing by regulatory ncRNA,M100,1,0
1,0,0,-2.2,0,0,GO:0009896,positive regulation of catabolic process,M100,1,0
1,0,0,-2.2,0,0,R-HSA-381119,Unfolded Protein Response (UPR),M100,1,0
1,0,0,-2.3,0,0,R-HSA-9673324,WNT5:FZD7-mediated leishmania damping,M100,1,0
1,0,0,-2.2,0,0,GO:0006979,response to oxidative stress,M100,1,0
1,0,0,-3.8,0,0,R-HSA-6783589,Interleukin-6 family signaling,M100,1,0
1,0,0,-2.9,0,0,GO:0043030,regulation of macrophage activation,M100,1,0
1,0,0,-2,0,0,GO:0010876,lipid localization,M100,1,0
1,0,0,-2.4,0,0,GO:0050729,positive regulation of inflammatory response,M100,1,0
1,0,0,-2.6,0,0,GO:0035590,purinergic nucleotide receptor signaling pathway,M100,1,0
1,0,0,-2.4,0,0,M134,PID TCR RAS PATHWAY,M100,1,0
1,0,0,-2.3,0,0,GO:0071727,cellular response to triacyl bacterial lipopeptide,M100,1,0
1,0,0,-2,0,0,GO:1905459,regulation of vascular associated smooth muscle cell apoptotic process,M100,1,0
1,0,0,-2.2,0,0,WP4787,Osteoblast differentiation and related diseases,M100,1,0
1,0,0,-3.7,0,0,R-HSA-9707616,Heme signaling,M100,1,0
1,0,0,-2.3,0,0,R-HSA-2562578,TRIF-mediated programmed cell death,M100,1,0
1,0,0,-6.5,0,0,GO:0048562,embryonic organ morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0043583,ear development,M100,1,0
1,0,0,-3.5,0,0,WP5090,Complement system in neuronal development and plasticity,M100,1,0
1,0,0,-2.6,0,0,GO:0032868,response to insulin,M100,1,0
1,0,0,-3.7,0,0,GO:0030857,negative regulation of epithelial cell differentiation,M100,1,0
0,1,0,0,-2.1,0,R-HSA-2559585,Oncogene Induced Senescence,M010,1,0
1,0,0,-2.1,0,0,GO:0097150,neuronal stem cell population maintenance,M100,1,0
0,1,0,0,-2.4,0,GO:0018108,peptidyl-tyrosine phosphorylation,M010,1,0
1,0,0,-2.3,0,0,R-HSA-1433559,Regulation of KIT signaling,M100,1,0
1,0,0,-2.3,0,0,CORUM:3054,MAD1-mSin3A-HDAC2 complex,M100,1,0
0,1,0,0,-2,0,GO:0002440,production of molecular mediator of immune response,M010,1,0
1,0,0,-2.6,0,0,GO:0021766,hippocampus development,M100,1,0
1,0,0,-2.3,0,0,GO:0045898,regulation of RNA polymerase II transcription preinitiation complex assembly,M100,1,0
1,0,0,-3.9,0,0,GO:0042509,regulation of tyrosine phosphorylation of STAT protein,M100,1,0
1,0,0,-2,0,0,GO:0042473,outer ear morphogenesis,M100,1,0
0,1,0,0,-2.2,0,GO:0032656,regulation of interleukin-13 production,M010,1,0
1,0,0,-4,0,0,GO:0031295,T cell costimulation,M100,1,0
1,0,0,-2,0,0,GO:0036294,cellular response to decreased oxygen levels,M100,1,0
1,0,0,-2.3,0,0,GO:0002767,immune response-inhibiting cell surface receptor signaling pathway,M100,1,0
1,0,0,-2.6,0,0,M223,PID BETA CATENIN NUC PATHWAY,M100,1,0
1,0,0,-4.1,0,0,M166,PID ATF2 PATHWAY,M100,1,0
1,0,0,-2.1,0,0,GO:1901343,negative regulation of vasculature development,M100,1,0
1,0,0,-2.3,0,0,R-HSA-8849473,PTK6 Expression,M100,1,0
0,1,0,0,-2.7,0,GO:0051100,negative regulation of binding,M010,1,0
1,0,0,-2.2,0,0,R-HSA-1234174,Cellular response to hypoxia,M100,1,0
1,0,0,-3.4,0,0,R-HSA-1257604,PIP3 activates AKT signaling,M100,1,0
0,1,0,0,-2.7,0,hsa04066,HIF-1 signaling pathway,M010,1,0
1,0,0,-2.5,0,0,GO:0007265,Ras protein signal transduction,M100,1,0
1,0,0,-2.4,0,0,WP4928,MAPK pathway in congenital thyroid cancer,M100,1,0
1,0,0,-3.4,0,0,R-HSA-381042,PERK regulates gene expression,M100,1,0
0,0,1,0,0,-2.1,R-HSA-448424,Interleukin-17 signaling,M001,1,0
1,0,0,-2.1,0,0,GO:0038061,non-canonical NF-kappaB signal transduction,M100,1,0
0,1,0,0,-2.2,0,GO:0016445,somatic diversification of immunoglobulins,M010,1,0
1,0,0,-3.7,0,0,GO:0010634,positive regulation of epithelial cell migration,M100,1,0
0,1,0,0,-2.5,0,R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,M010,1,0
1,0,0,-2.3,0,0,GO:0040029,epigenetic regulation of gene expression,M100,1,0
1,0,0,-2.8,0,0,GO:0021872,forebrain generation of neurons,M100,1,0
1,0,0,-9.2,0,0,GO:1901699,cellular response to nitrogen compound,M100,1,0
1,0,0,-2.6,0,0,hsa04917,Prolactin signaling pathway,M100,1,0
1,0,0,-4.4,0,0,GO:0001892,embryonic placenta development,M100,1,0
1,0,0,-3.1,0,0,GO:0032722,positive regulation of chemokine production,M100,1,0
1,0,0,-3.1,0,0,R-HSA-5607763,CLEC7A (Dectin-1) induces NFAT activation,M100,1,0
1,0,0,-2.9,0,0,GO:0051592,response to calcium ion,M100,1,0
1,0,0,-6.1,0,0,GO:0002244,hematopoietic progenitor cell differentiation,M100,1,0
1,0,0,-3.4,0,0,GO:0002221,pattern recognition receptor signaling pathway,M100,1,0
1,0,0,-2.4,0,0,WP1541,Energy metabolism,M100,1,0
1,0,0,-2.7,0,0,GO:0002701,negative regulation of production of molecular mediator of immune response,M100,1,0
1,0,0,-4.5,0,0,GO:0070482,response to oxygen levels,M100,1,0
1,0,0,-2.4,0,0,M68,PID RHOA REG PATHWAY,M100,1,0
1,0,0,-2.3,0,0,WP4655,Cytosolic DNA sensing pathway,M100,1,0
1,0,0,-6.2,0,0,GO:0002009,morphogenesis of an epithelium,M100,1,0
1,0,0,-5.6,0,0,WP364,IL6 signaling pathway,M100,1,0
1,0,0,-2.2,0,0,WP3981,miRNA regulation of prostate cancer signaling pathways,M100,1,0
1,0,0,-2,0,0,GO:0048340,paraxial mesoderm morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0044403,biological process involved in symbiotic interaction,M100,1,0
1,0,0,-3.4,0,0,GO:0060425,lung morphogenesis,M100,1,0
0,1,0,0,-3.4,0,CORUM:1777,"Ubiquitin E3 ligase (SMURF2, SMAD7) - TGF(beta)",M010,1,0
1,0,0,-4.2,0,0,WP4538,Regulatory circuits of the STAT3 signaling pathway,M100,1,0
1,0,0,-2.6,0,0,GO:0021795,cerebral cortex cell migration,M100,1,0
1,0,0,-2.3,0,0,GO:0007406,negative regulation of neuroblast proliferation,M100,1,0
1,0,0,-2.9,0,0,GO:0021799,cerebral cortex radially oriented cell migration,M100,1,0
0,1,0,0,-2.5,0,GO:0045586,regulation of gamma-delta T cell differentiation,M010,1,0
1,0,0,-4.4,0,0,GO:0071356,cellular response to tumor necrosis factor,M100,1,0
1,0,0,-2.7,0,0,R-HSA-9614085,FOXO-mediated transcription,M100,1,0
1,0,0,-6,0,0,GO:0048732,gland development,M100,1,0
0,1,0,0,-2.2,0,GO:0036075,replacement ossification,M010,1,0
1,0,0,-3.3,0,0,WP3851,TLR4 signaling and tolerance,M100,1,0
1,0,0,-2.7,0,0,GO:0070243,regulation of thymocyte apoptotic process,M100,1,0
1,0,0,-2.1,0,0,GO:2000181,negative regulation of blood vessel morphogenesis,M100,1,0
1,0,0,-4,0,0,GO:0035050,embryonic heart tube development,M100,1,0
1,0,0,-2,0,0,R-HSA-195721,Signaling by WNT,M100,1,0
1,0,0,-3.3,0,0,GO:0042752,regulation of circadian rhythm,M100,1,0
1,0,0,-4.4,0,0,GO:1901653,cellular response to peptide,M100,1,0
1,0,0,-2.7,0,0,GO:0071241,cellular response to inorganic substance,M100,1,0
1,0,0,-2.6,0,0,GO:1902074,response to salt,M100,1,0
1,0,0,-2.8,0,0,GO:0035162,embryonic hemopoiesis,M100,1,0
1,0,0,-3.1,0,0,R-HSA-9673770,Signaling by PDGFRA extracellular domain mutants,M100,1,0
1,0,0,-3.1,0,0,GO:1900015,regulation of cytokine production involved in inflammatory response,M100,1,0
1,0,0,-2.1,0,0,WP4535,Envelope proteins and their potential roles in EDMD physiopathology,M100,1,0
0,1,0,0,-3.4,0,GO:0001798,positive regulation of type IIa hypersensitivity,M010,1,0
1,0,0,-2.5,0,0,GO:0021761,limbic system development,M100,1,0
0,1,0,0,-2.8,0,GO:0002524,hypersensitivity,M010,1,0
0,1,0,0,-4.3,0,GO:0038093,Fc receptor signaling pathway,M010,1,0
1,0,0,-2.5,0,0,hsa05131,Shigellosis,M100,1,0
1,0,0,-2.9,0,0,R-HSA-383280,Nuclear Receptor transcription pathway,M100,1,0
1,0,0,-2.5,0,0,GO:0002688,regulation of leukocyte chemotaxis,M100,1,0
1,0,0,-2.3,0,0,GO:0045599,negative regulation of fat cell differentiation,M100,1,0
1,0,0,-2.6,0,0,GO:1990830,cellular response to leukemia inhibitory factor,M100,1,0
0,0,1,0,0,-2.6,WP3617,Photodynamic therapy induced NF kB survival signaling,M001,1,0
0,1,0,0,-2.2,0,GO:0045576,mast cell activation,M010,1,0
0,1,0,0,-3.6,0,GO:0016310,phosphorylation,M010,1,0
1,0,0,-4.7,0,0,hsa05134,Legionellosis,M100,1,0
1,0,0,-2.4,0,0,GO:0006869,lipid transport,M100,1,0
1,0,0,-3.2,0,0,GO:0045471,response to ethanol,M100,1,0
1,0,0,-3.9,0,0,GO:0010453,regulation of cell fate commitment,M100,1,0
1,0,0,-4.4,0,0,GO:1902894,negative regulation of miRNA transcription,M100,1,0
1,0,0,-2.1,0,0,R-HSA-5620971,Pyroptosis,M100,1,0
0,1,0,0,-2,0,WP4300,Extracellular vesicles in the crosstalk of cardiac cells,M010,1,0
1,0,0,-3.6,0,0,WP3931,Embryonic stem cell pluripotency pathways,M100,1,0
1,0,0,-2.3,0,0,R-HSA-9768777,Regulation of NPAS4 gene transcription,M100,1,0
1,0,0,-3.4,0,0,WP2873,Aryl hydrocarbon receptor pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0097012,response to granulocyte macrophage colony-stimulating factor,M100,1,0
1,0,0,-2.3,0,0,GO:0030833,regulation of actin filament polymerization,M100,1,0
1,0,0,-2.7,0,0,GO:0033209,tumor necrosis factor-mediated signaling pathway,M100,1,0
1,0,0,-2.7,0,0,GO:0001938,positive regulation of endothelial cell proliferation,M100,1,0
1,0,0,-3.1,0,0,R-HSA-9634815,Transcriptional Regulation by NPAS4,M100,1,0
1,0,0,-5.1,0,0,GO:0030509,BMP signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0035272,exocrine system development,M100,1,0
1,0,0,-3.1,0,0,R-HSA-1234158,Regulation of gene expression by Hypoxia-inducible Factor,M100,1,0
1,0,0,-5.2,0,0,GO:0045765,regulation of angiogenesis,M100,1,0
1,0,0,-2.7,0,0,GO:0008347,glial cell migration,M100,1,0
0,1,0,0,-2.4,0,GO:0045060,negative thymic T cell selection,M010,1,0
1,0,0,-2.9,0,0,WP3680,Physico chemical features and toxicity associated pathways,M100,1,0
1,0,0,-4,0,0,WP5087,Pleural mesothelioma,M100,1,0
1,0,0,-4.2,0,0,WP3303,RAC1 PAK1 p38 MMP2 pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0019058,viral life cycle,M100,1,0
1,0,0,-2.3,0,0,GO:0071725,response to triacyl bacterial lipopeptide,M100,1,0
0,1,0,0,-3.1,0,GO:0032480,negative regulation of type I interferon production,M010,1,0
1,0,0,-2.4,0,0,GO:0021772,olfactory bulb development,M100,1,0
1,0,0,-3.2,0,0,GO:0022029,telencephalon cell migration,M100,1,0
1,0,0,-3.1,0,0,GO:0071466,cellular response to xenobiotic stimulus,M100,1,0
0,0,1,0,0,-3.6,R-HSA-749476,RNA Polymerase III Abortive And Retractive Initiation,M001,1,0
1,0,0,-3.3,0,0,GO:0002223,stimulatory C-type lectin receptor signaling pathway,M100,1,0
0,1,0,0,-2.2,0,M71,PID ILK PATHWAY,M010,1,0
1,0,0,-2.9,0,0,GO:0035136,forelimb morphogenesis,M100,1,0
1,0,0,-2.3,0,0,R-HSA-936964,"Activation of IRF3, IRF7 mediated by TBK1, IKBKE",M100,1,0
0,1,0,0,-3.1,0,GO:0030852,regulation of granulocyte differentiation,M010,1,0
1,0,0,-2,0,0,M12705,SIG CD40PATHWAYMAP,M100,1,0
1,0,0,-3.8,0,0,M26,PID NFKAPPAB ATYPICAL PATHWAY,M100,1,0
1,0,0,-2,0,0,WP4481,Resistin as a regulator of inflammation,M100,1,0
1,0,0,-3,0,0,GO:0043401,steroid hormone mediated signaling pathway,M100,1,0
1,0,0,-3.3,0,0,GO:0090287,regulation of cellular response to growth factor stimulus,M100,1,0
0,1,0,0,-2.2,0,WP5385,Growth factors and hormones in Beta cell proliferation,M010,1,0
1,0,0,-4.9,0,0,GO:0045937,positive regulation of phosphate metabolic process,M100,1,0
1,0,0,-3.9,0,0,GO:0010952,positive regulation of peptidase activity,M100,1,0
0,1,0,0,-2.8,0,CORUM:2536,PLC-gamma-2-SLP-76-Lyn-Grb2 complex,M010,1,0
1,0,0,-2.1,0,0,GO:0035456,response to interferon-beta,M100,1,0
0,0,1,0,0,-2.1,R-HSA-1912422,Pre-NOTCH Expression and Processing,M001,1,0
1,0,0,-3.9,0,0,GO:0071383,cellular response to steroid hormone stimulus,M100,1,0
1,0,0,-2.8,0,0,GO:0070741,response to interleukin-6,M100,1,0
1,0,0,-2.2,0,0,GO:0001825,blastocyst formation,M100,1,0
1,0,0,-2.9,0,0,hsa04621,NOD-like receptor signaling pathway,M100,1,0
1,0,0,-3.3,0,0,WP732,Serotonin receptor 2 and ELK SRF GATA4 signaling,M100,1,0
1,0,0,-2,0,0,GO:0097154,GABAergic neuron differentiation,M100,1,0
1,0,0,-2.7,0,0,GO:0034616,response to laminar fluid shear stress,M100,1,0
1,0,0,-2,0,0,GO:0097152,mesenchymal cell apoptotic process,M100,1,0
1,0,0,-2.6,0,0,M234,PID IL2 STAT5 PATHWAY,M100,1,0
1,0,0,-2.2,0,0,WP1591,Heart development,M100,1,0
1,0,0,-3.1,0,0,GO:0043433,negative regulation of DNA-binding transcription factor activity,M100,1,0
1,0,0,-2.3,0,0,GO:0150076,neuroinflammatory response,M100,1,0
1,0,0,-4.9,0,0,R-HSA-937061,TRIF(TICAM1)-mediated TLR4 signaling,M100,1,0
0,1,0,0,-2.5,0,GO:0038095,Fc-epsilon receptor signaling pathway,M010,1,0
1,0,0,-2.9,0,0,GO:0010498,proteasomal protein catabolic process,M100,1,0
1,0,0,-2,0,0,CORUM:5230,CHUK-NFKB2-REL-IKBKG-SPAG9-NFKB1-NFKBIE-COPB2-TNIP1-NFKBIA-RELA-TNIP2 complex,M100,1,0
1,0,0,-2.3,0,0,GO:1903069,regulation of ER-associated ubiquitin-dependent protein catabolic process,M100,1,0
1,0,0,-3.3,0,0,GO:1990840,response to lectin,M100,1,0
0,1,0,0,-2.2,0,GO:0030890,positive regulation of B cell proliferation,M010,1,0
0,1,0,0,-2.6,0,hsa04750,Inflammatory mediator regulation of TRP channels,M010,1,0
1,0,0,-2.4,0,0,GO:0032808,lacrimal gland development,M100,1,0
1,0,0,-2,0,0,GO:0015908,fatty acid transport,M100,1,0
1,0,0,-3.1,0,0,GO:0022604,regulation of cell morphogenesis,M100,1,0
1,0,0,-2,0,0,GO:1901623,regulation of lymphocyte chemotaxis,M100,1,0
1,0,0,-2.8,0,0,GO:0008286,insulin receptor signaling pathway,M100,1,0
1,0,0,-4.7,0,0,GO:0009611,response to wounding,M100,1,0
1,0,0,-2.1,0,0,GO:0140895,cell surface toll-like receptor signaling pathway,M100,1,0
1,0,0,-3.6,0,0,WP4258,lncRNA in canonical Wnt signaling and colorectal cancer,M100,1,0
1,0,0,-2,0,0,GO:0045651,positive regulation of macrophage differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:1903900,regulation of viral life cycle,M100,1,0
1,0,0,-3.5,0,0,GO:0010721,negative regulation of cell development,M100,1,0
1,0,0,-3.1,0,0,WP4542,Leukocyte intrinsic Hippo pathway functions,M100,1,0
1,0,0,-2,0,0,GO:0015718,monocarboxylic acid transport,M100,1,0
1,0,0,-2,0,0,R-HSA-197264,Nicotinamide salvaging,M100,1,0
1,0,0,-2.3,0,0,GO:2000401,regulation of lymphocyte migration,M100,1,0
1,0,0,-3.1,0,0,hsa04211,Longevity regulating pathway,M100,1,0
1,0,0,-3.1,0,0,WP1539,Angiogenesis,M100,1,0
0,1,0,0,-2.8,0,M138,PID THROMBIN PAR4 PATHWAY,M010,1,0
1,0,0,-2.7,0,0,GO:0032869,cellular response to insulin stimulus,M100,1,0
1,0,0,-4.5,0,0,GO:0030324,lung development,M100,1,0
1,0,0,-2.6,0,0,GO:0055090,acylglycerol homeostasis,M100,1,0
0,1,0,0,-2.4,0,GO:0002866,positive regulation of acute inflammatory response to antigenic stimulus,M010,1,0
1,0,0,-2,0,0,GO:0045579,positive regulation of B cell differentiation,M100,1,0
1,0,0,-3.1,0,0,R-HSA-2172127,DAP12 interactions,M100,1,0
1,0,0,-2,0,0,GO:0001823,mesonephros development,M100,1,0
0,1,0,0,-2,0,GO:0006959,humoral immune response,M010,1,0
1,0,0,-2.3,0,0,CORUM:6299,ELK1-SAP1a-EWS-FLI-FLI complex,M100,1,0
0,0,1,0,0,-2.8,GO:0071470,cellular response to osmotic stress,M001,1,0
1,0,0,-6,0,0,GO:0045953,negative regulation of natural killer cell mediated cytotoxicity,M100,1,0
1,0,0,-3.4,0,0,GO:1904888,cranial skeletal system development,M100,1,0
1,0,0,-2.3,0,0,WP422,MAPK cascade,M100,1,0
1,0,0,-2,0,0,GO:0048617,embryonic foregut morphogenesis,M100,1,0
1,0,0,-2.3,0,0,GO:0150117,positive regulation of cell-substrate junction organization,M100,1,0
0,1,0,0,-3.9,0,GO:0002335,mature B cell differentiation,M010,1,0
1,0,0,-3.1,0,0,GO:0021801,cerebral cortex radial glia-guided migration,M100,1,0
1,0,0,-2.8,0,0,hsa04932,Non-alcoholic fatty liver disease,M100,1,0
1,0,0,-4.1,0,0,GO:0060485,mesenchyme development,M100,1,0
1,0,0,-2.3,0,0,R-HSA-2025928,Calcineurin activates NFAT,M100,1,0
1,0,0,-2.3,0,0,GO:0072539,T-helper 17 cell differentiation,M100,1,0
1,0,0,-2.3,0,0,GO:2001028,positive regulation of endothelial cell chemotaxis,M100,1,0
1,0,0,-2.3,0,0,GO:0045591,positive regulation of regulatory T cell differentiation,M100,1,0
1,0,0,-4.2,0,0,R-HSA-2262752,Cellular responses to stress,M100,1,0
1,0,0,-2.7,0,0,WP3611,Photodynamic therapy induced AP 1 survival signaling,M100,1,0
1,0,0,-2.3,0,0,R-HSA-5602498,MyD88 deficiency (TLR2/4),M100,1,0
1,0,0,-3.9,0,0,R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,M100,1,0
1,0,0,-3.1,0,0,GO:0048341,paraxial mesoderm formation,M100,1,0
0,1,0,0,-2.4,0,GO:0071801,regulation of podosome assembly,M010,1,0
1,0,0,-2.4,0,0,R-HSA-1236974,ER-Phagosome pathway,M100,1,0
1,0,0,-3.8,0,0,GO:0030336,negative regulation of cell migration,M100,1,0
1,0,0,-6.7,0,0,GO:0002716,negative regulation of natural killer cell mediated immunity,M100,1,0
1,0,0,-2.6,0,0,GO:0035115,embryonic forelimb morphogenesis,M100,1,0
1,0,0,-3,0,0,WP4685,Melanoma,M100,1,0
1,0,0,-2.7,0,0,GO:0001708,cell fate specification,M100,1,0
0,1,0,0,-2.2,0,M41,PID ER NONGENOMIC PATHWAY,M010,1,0
1,0,0,-2.3,0,0,GO:0045655,regulation of monocyte differentiation,M100,1,0
1,0,0,-3.1,0,0,GO:0002710,negative regulation of T cell mediated immunity,M100,1,0
1,0,0,-3.4,0,0,GO:0048524,positive regulation of viral process,M100,1,0
1,0,0,-3.8,0,0,WP22,IL 9 signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0042330,taxis,M100,1,0
0,1,0,0,-2.8,0,GO:0043305,negative regulation of mast cell degranulation,M010,1,0
1,0,0,-3.2,0,0,GO:2000177,regulation of neural precursor cell proliferation,M100,1,0
1,0,0,-2.7,0,0,R-HSA-8984722,Interleukin-35 Signalling,M100,1,0
1,0,0,-2.2,0,0,M279,PID RB 1PATHWAY,M100,1,0
1,0,0,-3.9,0,0,hsa05213,Endometrial cancer,M100,1,0
1,0,0,-3,0,0,GO:0007610,behavior,M100,1,0
1,0,0,-4.2,0,0,WP2637,Interleukin 1 IL 1 structural pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0046532,regulation of photoreceptor cell differentiation,M100,1,0
1,0,0,-3.3,0,0,WP3630,NAD metabolism sirtuins and aging,M100,1,0
0,0,1,0,0,-3.7,R-HSA-5621575,CD209 (DC-SIGN) signaling,M001,1,0
1,0,0,-3.9,0,0,GO:0036293,response to decreased oxygen levels,M100,1,0
1,0,0,-2.3,0,0,GO:0009952,anterior/posterior pattern specification,M100,1,0
1,0,0,-2.1,0,0,GO:0060349,bone morphogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0072163,mesonephric epithelium development,M100,1,0
1,0,0,-2.3,0,0,CORUM:1890,ELK1-SRF-ELK4 complex,M100,1,0
1,0,0,-2.3,0,0,CORUM:1232,REST-CoREST-mSIN3A complex,M100,1,0
0,1,0,0,-2.4,0,R-HSA-1266695,Interleukin-7 signaling,M010,1,0
1,0,0,-2.3,0,0,hsa05205,Proteoglycans in cancer,M100,1,0
1,0,0,-5.1,0,0,WP2355,Corticotropin releasing hormone signaling pathway,M100,1,0
1,0,0,-3.5,0,0,GO:0002643,regulation of tolerance induction,M100,1,0
1,0,0,-2.2,0,0,WP400,p38 MAPK signaling pathway,M100,1,0
1,0,0,-3.4,0,0,GO:0003151,outflow tract morphogenesis,M100,1,0
1,0,0,-2.9,0,0,GO:0052547,regulation of peptidase activity,M100,1,0
1,0,0,-2,0,0,GO:0007519,skeletal muscle tissue development,M100,1,0
1,0,0,-2.2,0,0,GO:0030901,midbrain development,M100,1,0
1,0,0,-2.5,0,0,GO:0060538,skeletal muscle organ development,M100,1,0
1,0,0,-2.7,0,0,GO:0010522,regulation of calcium ion transport into cytosol,M100,1,0
1,0,0,-2.8,0,0,GO:0043369,"CD4-positive or CD8-positive, alpha-beta T cell lineage commitment",M100,1,0
1,0,0,-2.7,0,0,R-HSA-8951671,RUNX3 regulates YAP1-mediated transcription,M100,1,0
1,0,0,-2.3,0,0,GO:1900027,regulation of ruffle assembly,M100,1,0
1,0,0,-2,0,0,WP4357,NRF2 ARE regulation,M100,1,0
1,0,0,-2.4,0,0,GO:0090009,primitive streak formation,M100,1,0
1,0,0,-2.1,0,0,GO:0048546,digestive tract morphogenesis,M100,1,0
1,0,0,-4,0,0,GO:0032729,positive regulation of type II interferon production,M100,1,0
1,0,0,-2.9,0,0,GO:0060326,cell chemotaxis,M100,1,0
0,1,0,0,-2.2,0,M238,PID THROMBIN PAR1 PATHWAY,M010,1,0
1,0,0,-2.1,0,0,R-HSA-202424,Downstream TCR signaling,M100,1,0
0,1,0,0,-2.3,0,hsa04015,Rap1 signaling pathway,M010,1,0
1,0,0,-2.7,0,0,R-HSA-111461,Cytochrome c-mediated apoptotic response,M100,1,0
1,0,0,-4.6,0,0,WP382,MAPK signaling pathway,M100,1,0
0,1,0,0,-2.5,0,GO:0046633,alpha-beta T cell proliferation,M010,1,0
1,0,0,-2.6,0,0,R-HSA-3214841,PKMTs methylate histone lysines,M100,1,0
0,1,0,0,-2.2,0,GO:0030854,positive regulation of granulocyte differentiation,M010,1,0
1,0,0,-4.4,0,0,GO:1903530,regulation of secretion by cell,M100,1,0
0,1,0,0,-2.2,0,R-HSA-392518,Signal amplification,M010,1,0
1,0,0,-7.5,0,0,GO:0031342,negative regulation of cell killing,M100,1,0
1,0,0,-2.4,0,0,WP4808,Endochondral ossification with skeletal dysplasias,M100,1,0
1,0,0,-2.3,0,0,GO:0060539,diaphragm development,M100,1,0
1,0,0,-2.1,0,0,M121,PID MTOR 4PATHWAY,M100,1,0
1,0,0,-4.1,0,0,hsa04144,Endocytosis,M100,1,0
0,1,0,0,-2.3,0,M8,PID ENDOTHELIN PATHWAY,M010,1,0
1,0,0,-2.1,0,0,GO:0045921,positive regulation of exocytosis,M100,1,0
1,0,0,-2.3,0,0,GO:0043632,modification-dependent macromolecule catabolic process,M100,1,0
1,0,0,-5.9,0,0,GO:0071222,cellular response to lipopolysaccharide,M100,1,0
1,0,0,-2.3,0,0,GO:0030512,negative regulation of transforming growth factor beta receptor signaling pathway,M100,1,0
1,0,0,-13,0,0,GO:0071407,cellular response to organic cyclic compound,M100,1,0
0,1,0,0,-3,0,GO:0045588,positive regulation of gamma-delta T cell differentiation,M010,1,0
1,0,0,-2,0,0,M137,PID VEGF VEGFR PATHWAY,M100,1,0
1,0,0,-4.9,0,0,GO:0030900,forebrain development,M100,1,0
1,0,0,-6.2,0,0,GO:0032945,negative regulation of mononuclear cell proliferation,M100,1,0
1,0,0,-5,0,0,GO:0042269,regulation of natural killer cell mediated cytotoxicity,M100,1,0
1,0,0,-2.3,0,0,GO:0006935,chemotaxis,M100,1,0
1,0,0,-3.3,0,0,GO:0070102,interleukin-6-mediated signaling pathway,M100,1,0
1,0,0,-3.4,0,0,GO:0009410,response to xenobiotic stimulus,M100,1,0
1,0,0,-2.9,0,0,GO:0042476,odontogenesis,M100,1,0
1,0,0,-2.4,0,0,GO:0010001,glial cell differentiation,M100,1,0
1,0,0,-2.7,0,0,R-HSA-9006931,Signaling by Nuclear Receptors,M100,1,0
1,0,0,-2.3,0,0,GO:0038154,interleukin-11-mediated signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0060147,regulation of post-transcriptional gene silencing,M100,1,0
1,0,0,-4.7,0,0,GO:0031343,positive regulation of cell killing,M100,1,0
0,1,0,0,-2.8,0,GO:1905005,regulation of epithelial to mesenchymal transition involved in endocardial cushion formation,M010,1,0
1,0,0,-3.3,0,0,WP4754,IL 18 signaling pathway,M100,1,0
0,1,0,0,-4.8,0,R-HSA-2029485,Role of phospholipids in phagocytosis,M010,1,0
1,0,0,-2,0,0,GO:0060143,positive regulation of syncytium formation by plasma membrane fusion,M100,1,0
1,0,0,-3.2,0,0,GO:1904892,regulation of receptor signaling pathway via STAT,M100,1,0
1,0,0,-2.3,0,0,GO:0035065,regulation of histone acetylation,M100,1,0
1,0,0,-4,0,0,R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,M100,1,0
1,0,0,-2.3,0,0,GO:1902176,negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,M100,1,0
1,0,0,-4.9,0,0,R-HSA-166166,MyD88-independent TLR4 cascade,M100,1,0
1,0,0,-3.1,0,0,GO:0043373,"CD4-positive, alpha-beta T cell lineage commitment",M100,1,0
1,0,0,-2.3,0,0,CORUM:1257,ALL-1 supercomplex,M100,1,0
1,0,0,-3.5,0,0,GO:0042471,ear morphogenesis,M100,1,0
1,0,0,-8.9,0,0,GO:0071417,cellular response to organonitrogen compound,M100,1,0
1,0,0,-2.7,0,0,GO:0007623,circadian rhythm,M100,1,0
1,0,0,-2.1,0,0,GO:0006109,regulation of carbohydrate metabolic process,M100,1,0
1,0,0,-3,0,0,GO:0002065,columnar/cuboidal epithelial cell differentiation,M100,1,0
1,0,0,-2.6,0,0,R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,M100,1,0
1,0,0,-2.7,0,0,GO:2000179,positive regulation of neural precursor cell proliferation,M100,1,0
1,0,0,-2,0,0,R-HSA-9020956,Interleukin-27 signaling,M100,1,0
1,0,0,-2.6,0,0,M241,PID RAC1 REG PATHWAY,M100,1,0
1,0,0,-4.4,0,0,hsa05160,Hepatitis C,M100,1,0
1,0,0,-4.4,0,0,GO:0002053,positive regulation of mesenchymal cell proliferation,M100,1,0
1,0,0,-2.9,0,0,GO:0002052,positive regulation of neuroblast proliferation,M100,1,0
1,0,0,-5,0,0,GO:0060562,epithelial tube morphogenesis,M100,1,0
1,0,0,-3.9,0,0,GO:0045766,positive regulation of angiogenesis,M100,1,0
0,1,0,0,-2.5,0,R-HSA-5689603,UCH proteinases,M010,1,0
1,0,0,-3.1,0,0,WP428,Wnt signaling,M100,1,0
1,0,0,-3.5,0,0,GO:2000146,negative regulation of cell motility,M100,1,0
0,0,1,0,0,-2,M254,PID MYC REPRESS PATHWAY,M001,1,0
1,0,0,-3.8,0,0,GO:0042593,glucose homeostasis,M100,1,0
1,0,0,-2.4,0,0,GO:0071322,cellular response to carbohydrate stimulus,M100,1,0
1,0,0,-2.6,0,0,GO:0060444,branching involved in mammary gland duct morphogenesis,M100,1,0
0,1,0,0,-3.9,0,hsa05223,Non-small cell lung cancer,M010,1,0
1,0,0,-3.9,0,0,WP3888,VEGFA VEGFR2 signaling,M100,1,0
1,0,0,-2,0,0,CORUM:5233,TNF-alpha/NF-kappa B signaling complex 5,M100,1,0
1,0,0,-4,0,0,R-HSA-6807070,PTEN Regulation,M100,1,0
1,0,0,-2.3,0,0,GO:0001916,positive regulation of T cell mediated cytotoxicity,M100,1,0
1,0,0,-2.4,0,0,GO:0009267,cellular response to starvation,M100,1,0
1,0,0,-3.1,0,0,R-HSA-9673767,"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",M100,1,0
1,0,0,-3.9,0,0,R-HSA-388841,Costimulation by the CD28 family,M100,1,0
0,1,0,0,-2.2,0,WP4971,Phosphoinositides metabolism,M010,1,0
1,0,0,-3.7,0,0,GO:0045332,phospholipid translocation,M100,1,0
1,0,0,-3.2,0,0,GO:0002067,glandular epithelial cell differentiation,M100,1,0
1,0,0,-7.3,0,0,hsa04936,Alcoholic liver disease,M100,1,0
1,0,0,-2.7,0,0,R-HSA-1168372,Downstream signaling events of B Cell Receptor (BCR),M100,1,0
1,0,0,-3.5,0,0,CORUM:642,CtBP complex,M100,1,0
1,0,0,-2,0,0,WP195,IL 1 signaling pathway,M100,1,0
1,0,0,-3.1,0,0,R-HSA-9627069,Regulation of the apoptosome activity,M100,1,0
0,1,0,0,-2.2,0,WP4904,LDLRAD4 and what we know about it,M010,1,0
1,0,0,-2,0,0,M135,PID IL5 PATHWAY,M100,1,0
1,0,0,-3.9,0,0,GO:0043124,negative regulation of canonical NF-kappaB signal transduction,M100,1,0
1,0,0,-5,0,0,GO:0001568,blood vessel development,M100,1,0
1,0,0,-2.6,0,0,GO:2000116,regulation of cysteine-type endopeptidase activity,M100,1,0
1,0,0,-2.4,0,0,GO:0032753,positive regulation of interleukin-4 production,M100,1,0
0,1,0,0,-3.4,0,GO:0001771,immunological synapse formation,M010,1,0
1,0,0,-4.5,0,0,GO:1901654,response to ketone,M100,1,0
1,0,0,-2.3,0,0,R-HSA-9664420,Killing mechanisms,M100,1,0
0,1,0,0,-2.3,0,M175,PID ERBB2 ERBB3 PATHWAY,M010,1,0
1,0,0,-3.3,0,0,WP5417,Cell lineage map for neuronal differentiation,M100,1,0
0,1,0,0,-3.4,0,CORUM:2910,PLC-gamma-2-Lyn-FcR-gamma complex,M010,1,0
1,0,0,-3,0,0,hsa04022,cGMP-PKG signaling pathway,M100,1,0
1,0,0,-2.3,0,0,hsa05010,Alzheimer disease,M100,1,0
1,0,0,-4.9,0,0,WP4155,Endometrial cancer,M100,1,0
0,1,0,0,-3.4,0,CORUM:2997,Ubiquitin E3 ligase (SMAD7-SMURF1) - TGF(beta),M010,1,0
1,0,0,-2.9,0,0,WP2059,Alzheimer 39 s disease and miRNA effects,M100,1,0
1,0,0,-3.3,0,0,GO:0098743,cell aggregation,M100,1,0
1,0,0,-2.4,0,0,GO:0045666,positive regulation of neuron differentiation,M100,1,0
1,0,0,-2.6,0,0,GO:0042060,wound healing,M100,1,0
1,0,0,-2.7,0,0,WP205,IL 7 signaling pathway,M100,1,0
0,0,1,0,0,-2.7,GO:0051092,positive regulation of NF-kappaB transcription factor activity,M001,1,0
1,0,0,-2.3,0,0,WP4494,Selective expression of chemokine receptors during T cell polarization,M100,1,0
1,0,0,-2.5,0,0,GO:0017015,regulation of transforming growth factor beta receptor signaling pathway,M100,1,0
0,1,0,0,-2.2,0,hsa05150,Staphylococcus aureus infection,M010,1,0
1,0,0,-4.4,0,0,GO:0051960,regulation of nervous system development,M100,1,0
1,0,0,-2.3,0,0,GO:0090183,regulation of kidney development,M100,1,0
1,0,0,-2,0,0,GO:1901329,regulation of odontoblast differentiation,M100,1,0
1,0,0,-3.1,0,0,GO:0042270,protection from natural killer cell mediated cytotoxicity,M100,1,0
1,0,0,-2.1,0,0,GO:0002753,cytoplasmic pattern recognition receptor signaling pathway,M100,1,0
1,0,0,-3.5,0,0,GO:0051603,proteolysis involved in protein catabolic process,M100,1,0
0,1,0,0,-2.4,0,GO:0002863,positive regulation of inflammatory response to antigenic stimulus,M010,1,0
1,0,0,-2.1,0,0,GO:0010463,mesenchymal cell proliferation,M100,1,0
1,0,0,-3.9,0,0,GO:0098727,maintenance of cell number,M100,1,0
1,0,0,-2.6,0,0,M159,PID AMB2 NEUTROPHILS PATHWAY,M100,1,0
1,0,0,-2.3,0,0,GO:0097396,response to interleukin-17,M100,1,0
1,0,0,-2.3,0,0,GO:2000756,regulation of peptidyl-lysine acetylation,M100,1,0
1,0,0,-2.3,0,0,GO:0051894,positive regulation of focal adhesion assembly,M100,1,0
1,0,0,-2.3,0,0,GO:0061026,cardiac muscle tissue regeneration,M100,1,0
1,0,0,-2.9,0,0,GO:0090102,cochlea development,M100,1,0
1,0,0,-2.5,0,0,GO:0046425,regulation of receptor signaling pathway via JAK-STAT,M100,1,0
1,0,0,-3.1,0,0,hsa05133,Pertussis,M100,1,0
1,0,0,-2.6,0,0,M23,PID WNT NONCANONICAL PATHWAY,M100,1,0
1,0,0,-3,0,0,WP4321,Thermogenesis,M100,1,0
0,0,1,0,0,-2.4,GO:0050688,regulation of defense response to virus,M001,1,0
1,0,0,-6.3,0,0,GO:0048871,multicellular organismal-level homeostasis,M100,1,0
1,0,0,-4,0,0,WP4298,Acute viral myocarditis,M100,1,0
1,0,0,-3.1,0,0,GO:0016444,somatic cell DNA recombination,M100,1,0
1,0,0,-2.8,0,0,GO:0002363,alpha-beta T cell lineage commitment,M100,1,0
1,0,0,-2.9,0,0,GO:0045616,regulation of keratinocyte differentiation,M100,1,0
1,0,0,-3.3,0,0,GO:0097529,myeloid leukocyte migration,M100,1,0
1,0,0,-3.9,0,0,GO:0043536,positive regulation of blood vessel endothelial cell migration,M100,1,0
1,0,0,-5.2,0,0,GO:0045862,positive regulation of proteolysis,M100,1,0
1,0,0,-3.9,0,0,GO:0001666,response to hypoxia,M100,1,0
1,0,0,-2.4,0,0,GO:0002486,"antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent",M100,1,0
1,0,0,-3.3,0,0,GO:0035019,somatic stem cell population maintenance,M100,1,0
1,0,0,-2,0,0,GO:0002475,antigen processing and presentation via MHC class Ib,M100,1,0
1,0,0,-2.7,0,0,GO:0048857,neural nucleus development,M100,1,0
1,0,0,-3.7,0,0,GO:0048339,paraxial mesoderm development,M100,1,0
1,0,0,-4,0,0,GO:0061180,mammary gland epithelium development,M100,1,0
1,0,0,-2.1,0,0,GO:0032271,regulation of protein polymerization,M100,1,0
1,0,0,-2,0,0,GO:0009756,carbohydrate mediated signaling,M100,1,0
1,0,0,-2.9,0,0,GO:0031669,cellular response to nutrient levels,M100,1,0
0,1,0,0,-2.8,0,R-HSA-9020558,Interleukin-2 signaling,M010,1,0
1,0,0,-2.6,0,0,GO:0043161,proteasome-mediated ubiquitin-dependent protein catabolic process,M100,1,0
1,0,0,-2.4,0,0,GO:0071453,cellular response to oxygen levels,M100,1,0
1,0,0,-2.3,0,0,R-HSA-9020958,Interleukin-21 signaling,M100,1,0
1,0,0,-4.5,0,0,GO:0048863,stem cell differentiation,M100,1,0
1,0,0,-2,0,0,GO:0036336,dendritic cell migration,M100,1,0
1,0,0,-4.6,0,0,GO:0030323,respiratory tube development,M100,1,0
1,0,0,-2.3,0,0,GO:0015909,long-chain fatty acid transport,M100,1,0
1,0,0,-2.3,0,0,GO:0060440,trachea formation,M100,1,0
1,0,0,-2.3,0,0,GO:0062012,regulation of small molecule metabolic process,M100,1,0
0,0,1,0,0,-2.8,WP2865,IL1 and megakaryocytes in obesity,M001,1,0
1,0,0,-2.9,0,0,WP384,Apoptosis modulation by HSP70,M100,1,0
1,0,0,-3.1,0,0,WP2332,Interleukin 11 signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:1903071,positive regulation of ER-associated ubiquitin-dependent protein catabolic process,M100,1,0
1,0,0,-4.5,0,0,hsa05418,Fluid shear stress and atherosclerosis,M100,1,0
1,0,0,-2.3,0,0,GO:0060218,hematopoietic stem cell differentiation,M100,1,0
1,0,0,-2.3,0,0,M275,PID ALPHA SYNUCLEIN PATHWAY,M100,1,0
1,0,0,-2,0,0,WP4872,MAP3K1 role in promoting and blocking gonadal determination,M100,1,0
1,0,0,-3.3,0,0,WP4337,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,M100,1,0
1,0,0,-2.3,0,0,hsa04714,Thermogenesis,M100,1,0
1,0,0,-3.4,0,0,GO:0014013,regulation of gliogenesis,M100,1,0
1,0,0,-3.7,0,0,R-HSA-380994,ATF4 activates genes in response to endoplasmic reticulum  stress,M100,1,0
1,0,0,-3.8,0,0,WP5063,FOXP3 in COVID 19,M100,1,0
0,1,0,0,-2.8,0,GO:0002883,regulation of hypersensitivity,M010,1,0
1,0,0,-2.1,0,0,GO:2000377,regulation of reactive oxygen species metabolic process,M100,1,0
1,0,0,-3.2,0,0,hsa05164,Influenza A,M100,1,0
1,0,0,-2.3,0,0,GO:0001947,heart looping,M100,1,0
1,0,0,-2.6,0,0,GO:0060441,epithelial tube branching involved in lung morphogenesis,M100,1,0
1,0,0,-2.3,0,0,GO:1900017,positive regulation of cytokine production involved in inflammatory response,M100,1,0
1,0,0,-2,0,0,GO:0110110,positive regulation of animal organ morphogenesis,M100,1,0
0,1,0,0,-2.6,0,GO:0002449,lymphocyte mediated immunity,M010,1,0
0,1,0,0,-2.8,0,GO:0002445,type II hypersensitivity,M010,1,0
1,0,0,-5.3,0,0,hsa04550,Signaling pathways regulating pluripotency of stem cells,M100,1,0
1,0,0,-2.3,0,0,GO:0051099,positive regulation of binding,M100,1,0
0,1,0,0,-3.4,0,GO:0042092,type 2 immune response,M010,1,0
0,1,0,0,-2.2,0,GO:0060350,endochondral bone morphogenesis,M010,1,0
1,0,0,-4,0,0,hsa04210,Apoptosis,M100,1,0
1,0,0,-3.6,0,0,GO:0030855,epithelial cell differentiation,M100,1,0
1,0,0,-3.6,0,0,GO:0002719,negative regulation of cytokine production involved in immune response,M100,1,0
1,0,0,-2.8,0,0,GO:0042659,regulation of cell fate specification,M100,1,0
1,0,0,-4.9,0,0,GO:0010562,positive regulation of phosphorus metabolic process,M100,1,0
1,0,0,-3.1,0,0,GO:0097035,regulation of membrane lipid distribution,M100,1,0
1,0,0,-2,0,0,GO:0001945,lymph vessel development,M100,1,0
1,0,0,-2.4,0,0,GO:0071346,cellular response to type II interferon,M100,1,0
1,0,0,-2,0,0,GO:0055057,neuroblast division,M100,1,0
1,0,0,-2.4,0,0,GO:0046533,negative regulation of photoreceptor cell differentiation,M100,1,0
1,0,0,-2,0,0,WP2815,Mammary gland development pathway Involution Stage 4 of 4,M100,1,0
1,0,0,-2.4,0,0,GO:0010837,regulation of keratinocyte proliferation,M100,1,0
1,0,0,-4.5,0,0,GO:0043254,regulation of protein-containing complex assembly,M100,1,0
1,0,0,-2.6,0,0,WP4211,Transcriptional cascade regulating adipogenesis,M100,1,0
1,0,0,-2.3,0,0,GO:0048289,isotype switching to IgE isotypes,M100,1,0
1,0,0,-2.4,0,0,CORUM:725,P2X7 receptor signalling complex,M100,1,0
1,0,0,-2.6,0,0,GO:0060337,type I interferon-mediated signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0031056,regulation of histone modification,M100,1,0
1,0,0,-4,0,0,WP2112,IL 17 signaling pathway,M100,1,0
1,0,0,-5.2,0,0,GO:0007420,brain development,M100,1,0
1,0,0,-4.2,0,0,WP2328,Allograft rejection,M100,1,0
1,0,0,-2.2,0,0,GO:0090092,regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M100,1,0
1,0,0,-3.8,0,0,GO:0021537,telencephalon development,M100,1,0
1,0,0,-2.3,0,0,WP5102,Familial partial lipodystrophy,M100,1,0
0,1,0,0,-3.4,0,GO:0002894,positive regulation of type II hypersensitivity,M010,1,0
0,1,0,0,-2,0,GO:0060907,positive regulation of macrophage cytokine production,M010,1,0
1,0,0,-2.9,0,0,GO:0060760,positive regulation of response to cytokine stimulus,M100,1,0
1,0,0,-3.4,0,0,GO:0031668,cellular response to extracellular stimulus,M100,1,0
0,1,0,0,-2.2,0,GO:0031401,positive regulation of protein modification process,M010,1,0
1,0,0,-3.3,0,0,GO:0001502,cartilage condensation,M100,1,0
0,1,0,0,-2.5,0,GO:0045730,respiratory burst,M010,1,0
1,0,0,-2,0,0,WP5033,Genes associated with the development of rheumatoid arthritis,M100,1,0
1,0,0,-2.4,0,0,R-HSA-109606,Intrinsic Pathway for Apoptosis,M100,1,0
1,0,0,-2.4,0,0,GO:0061550,cranial ganglion development,M100,1,0
1,0,0,-2,0,0,GO:2000317,negative regulation of T-helper 17 type immune response,M100,1,0
1,0,0,-2.7,0,0,WP4814,Somatic sex determination,M100,1,0
1,0,0,-2.4,0,0,WP4336,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,M100,1,0
1,0,0,-2.2,0,0,M100,PID SHP2 PATHWAY,M100,1,0
0,1,0,0,-2.1,0,GO:0030101,natural killer cell activation,M010,1,0
1,0,0,-2.7,0,0,GO:0032695,negative regulation of interleukin-12 production,M100,1,0
1,0,0,-2.3,0,0,WP3599,Transcription factor regulation in adipogenesis,M100,1,0
1,0,0,-4.3,0,0,R-HSA-9013148,CDC42 GTPase cycle,M100,1,0
1,0,0,-2.4,0,0,GO:0097011,cellular response to granulocyte macrophage colony-stimulating factor stimulus,M100,1,0
1,0,0,-2.9,0,0,GO:1903531,negative regulation of secretion by cell,M100,1,0
0,1,0,0,-2.3,0,GO:0001773,myeloid dendritic cell activation,M010,1,0
1,0,0,-2.1,0,0,GO:0002752,cell surface pattern recognition receptor signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0002437,inflammatory response to antigenic stimulus,M100,1,0
1,0,0,-2.4,0,0,R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,M100,1,0
1,0,0,-2.3,0,0,GO:0048596,embryonic camera-type eye morphogenesis,M100,1,0
1,0,0,-4,0,0,GO:0010950,positive regulation of endopeptidase activity,M100,1,0
1,0,0,-2.2,0,0,GO:0072164,mesonephric tubule development,M100,1,0
1,0,0,-2.6,0,0,M197,PID HIV NEF PATHWAY,M100,1,0
1,0,0,-2.6,0,0,hsa04514,Cell adhesion molecules,M100,1,0
1,0,0,-2.4,0,0,WP4331,Neovascularisation processes,M100,1,0
0,1,0,0,-3.8,0,GO:0032688,negative regulation of interferon-beta production,M010,1,0
1,0,0,-7.2,0,0,GO:0002707,negative regulation of lymphocyte mediated immunity,M100,1,0
1,0,0,-2.3,0,0,WP2249,Metastatic brain tumor,M100,1,0
1,0,0,-3,0,0,R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,M100,1,0
0,1,0,0,-3.4,0,GO:0060986,endocrine hormone secretion,M010,1,0
1,0,0,-2.6,0,0,GO:0032652,regulation of interleukin-1 production,M100,1,0
1,0,0,-2.2,0,0,M276,PID FGF PATHWAY,M100,1,0
1,0,0,-2.9,0,0,WP619,Type II interferon signaling,M100,1,0
1,0,0,-3.1,0,0,R-HSA-111458,Formation of apoptosome,M100,1,0
1,0,0,-3.6,0,0,GO:0001912,positive regulation of leukocyte mediated cytotoxicity,M100,1,0
1,0,0,-2.3,0,0,GO:0002467,germinal center formation,M100,1,0
1,0,0,-3.2,0,0,hsa04612,Antigen processing and presentation,M100,1,0
0,1,0,0,-2.2,0,GO:0043383,negative T cell selection,M010,1,0
1,0,0,-2.6,0,0,GO:0034728,nucleosome organization,M100,1,0
1,0,0,-2.2,0,0,GO:0007584,response to nutrient,M100,1,0
1,0,0,-6.2,0,0,GO:0032870,cellular response to hormone stimulus,M100,1,0
1,0,0,-4.7,0,0,GO:0097305,response to alcohol,M100,1,0
1,0,0,-2.5,0,0,WP2853,Endoderm differentiation,M100,1,0
1,0,0,-2,0,0,R-HSA-9701898,STAT3 nuclear events downstream of ALK signaling,M100,1,0
1,0,0,-3.1,0,0,GO:0090077,foam cell differentiation,M100,1,0
1,0,0,-2.3,0,0,GO:1902869,regulation of amacrine cell differentiation,M100,1,0
1,0,0,-3.1,0,0,GO:0016045,detection of bacterium,M100,1,0
1,0,0,-2,0,0,GO:0045647,negative regulation of erythrocyte differentiation,M100,1,0
1,0,0,-2.3,0,0,CORUM:5162,ELK1-SRF-ELK3 complex,M100,1,0
1,0,0,-2.1,0,0,WP4871,Kisspeptin kisspeptin receptor system in the ovary,M100,1,0
1,0,0,-3.3,0,0,GO:1990858,cellular response to lectin,M100,1,0
1,0,0,-4.4,0,0,WP2263,Androgen receptor network in prostate cancer,M100,1,0
1,0,0,-6.5,0,0,GO:0001763,morphogenesis of a branching structure,M100,1,0
1,0,0,-4.3,0,0,GO:0006338,chromatin remodeling,M100,1,0
1,0,0,-2.3,0,0,R-HSA-5686938,Regulation of TLR by endogenous ligand,M100,1,0
1,0,0,-2.3,0,0,GO:0002309,T cell proliferation involved in immune response,M100,1,0
1,0,0,-4.2,0,0,GO:0048511,rhythmic process,M100,1,0
1,0,0,-3.7,0,0,GO:0031294,lymphocyte costimulation,M100,1,0
1,0,0,-3.1,0,0,WP1559,Transcription factors regulate miRNAs related to cardiac hypertrophy,M100,1,0
1,0,0,-3.7,0,0,GO:0016032,viral process,M100,1,0
1,0,0,-3.6,0,0,WP3932,Focal adhesion PI3K Akt mTOR signaling pathway,M100,1,0
1,0,0,-3,0,0,GO:0050769,positive regulation of neurogenesis,M100,1,0
1,0,0,-2.7,0,0,GO:0051591,response to cAMP,M100,1,0
0,1,0,0,-2.3,0,GO:0045807,positive regulation of endocytosis,M010,1,0
1,0,0,-3.3,0,0,GO:0001678,intracellular glucose homeostasis,M100,1,0
1,0,0,-3.5,0,0,GO:0032922,circadian regulation of gene expression,M100,1,0
1,0,0,-3.3,0,0,WP5352,10q11 21q11 23 copy number variation syndrome,M100,1,0
1,0,0,-3.3,0,0,hsa04915,Estrogen signaling pathway,M100,1,0
1,0,0,-4.2,0,0,GO:0010632,regulation of epithelial cell migration,M100,1,0
0,1,0,0,-2.7,0,R-HSA-114604,GPVI-mediated activation cascade,M010,1,0
1,0,0,-2,0,0,GO:2000320,negative regulation of T-helper 17 cell differentiation,M100,1,0
1,0,0,-2.3,0,0,GO:1905461,positive regulation of vascular associated smooth muscle cell apoptotic process,M100,1,0
1,0,0,-2.1,0,0,GO:0048010,vascular endothelial growth factor receptor signaling pathway,M100,1,0
0,1,0,0,-2.4,0,R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,M010,1,0
1,0,0,-2.3,0,0,GO:0045669,positive regulation of osteoblast differentiation,M100,1,0
1,0,0,-3.6,0,0,M164,PID ERBB1 DOWNSTREAM PATHWAY,M100,1,0
1,0,0,-2,0,0,GO:1903146,regulation of autophagy of mitochondrion,M100,1,0
1,0,0,-2.6,0,0,GO:0002507,tolerance induction,M100,1,0
1,0,0,-3.9,0,0,GO:0048545,response to steroid hormone,M100,1,0
1,0,0,-2.3,0,0,WP53,ID signaling pathway,M100,1,0
1,0,0,-4.3,0,0,GO:0043065,positive regulation of apoptotic process,M100,1,0
1,0,0,-4.2,0,0,hsa04148,Efferocytosis,M100,1,0
1,0,0,-2.7,0,0,GO:1903844,regulation of cellular response to transforming growth factor beta stimulus,M100,1,0
1,0,0,-2.4,0,0,GO:0048864,stem cell development,M100,1,0
1,0,0,-3.7,0,0,GO:0060537,muscle tissue development,M100,1,0
1,0,0,-2.3,0,0,hsa04910,Insulin signaling pathway,M100,1,0
1,0,0,-2.7,0,0,R-HSA-1236975,Antigen processing-Cross presentation,M100,1,0
1,0,0,-4,0,0,GO:0006325,chromatin organization,M100,1,0
1,0,0,-2.2,0,0,GO:1902459,positive regulation of stem cell population maintenance,M100,1,0
1,0,0,-2.9,0,0,WP4320,Effect of progerin on genes involved in Hutchinson Gilford progeria syndrome,M100,1,0
1,0,0,-4.4,0,0,GO:0042130,negative regulation of T cell proliferation,M100,1,0
1,0,0,-2,0,0,WP4949,16p11 2 proximal deletion syndrome,M100,1,0
1,0,0,-4.2,0,0,GO:0002220,innate immune response activating cell surface receptor signaling pathway,M100,1,0
1,0,0,-4.4,0,0,GO:2000629,negative regulation of miRNA metabolic process,M100,1,0
0,0,1,0,0,-2.5,R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),M001,1,0
1,0,0,-4,0,0,hsa04668,TNF signaling pathway,M100,1,0
1,0,0,-5.3,0,0,GO:0002715,regulation of natural killer cell mediated immunity,M100,1,0
0,1,0,0,-2.2,0,GO:0003222,ventricular trabecula myocardium morphogenesis,M010,1,0
1,0,0,-2.3,0,0,hsa04064,NF-kappa B signaling pathway,M100,1,0
1,0,0,-2.7,0,0,R-HSA-73980,RNA Polymerase III Transcription Termination,M100,1,0
1,0,0,-2.2,0,0,GO:0051051,negative regulation of transport,M100,1,0
1,0,0,-2.7,0,0,GO:0030593,neutrophil chemotaxis,M100,1,0
1,0,0,-3.1,0,0,hsa05016,Huntington disease,M100,1,0
1,0,0,-3.7,0,0,GO:0043535,regulation of blood vessel endothelial cell migration,M100,1,0
1,0,0,-3.2,0,0,GO:0050680,negative regulation of epithelial cell proliferation,M100,1,0
1,0,0,-3.4,0,0,R-HSA-9031628,NGF-stimulated transcription,M100,1,0
1,0,0,-2.6,0,0,WP4540,Hippo signaling regulation pathways,M100,1,0
1,0,0,-3.3,0,0,GO:1901655,cellular response to ketone,M100,1,0
1,0,0,-2.3,0,0,GO:0045661,regulation of myoblast differentiation,M100,1,0
0,1,0,0,-2.3,0,GO:2000319,regulation of T-helper 17 cell differentiation,M010,1,0
1,0,0,-2,0,0,R-HSA-1226099,Signaling by FGFR in disease,M100,1,0
1,0,0,-2.2,0,0,WP289,Myometrial relaxation and contraction pathways,M100,1,0
1,0,0,-4.5,0,0,GO:0032715,negative regulation of interleukin-6 production,M100,1,0
0,1,0,0,-2.2,0,GO:0048709,oligodendrocyte differentiation,M010,1,0
0,1,0,0,-3.4,0,GO:0002892,regulation of type II hypersensitivity,M010,1,0
0,1,0,0,-3.7,0,M169,PID INTEGRIN2 PATHWAY,M010,1,0
1,0,0,-2.7,0,0,GO:0001961,positive regulation of cytokine-mediated signaling pathway,M100,1,0
1,0,0,-4.8,0,0,GO:0031663,lipopolysaccharide-mediated signaling pathway,M100,1,0
1,0,0,-11,0,0,GO:0009792,embryo development ending in birth or egg hatching,M100,1,0
